



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Mobile health applications for intervention in children with overweight. A protocol for systematic review with Trial Sequential Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032570
Article Type:	Protocol
Date Submitted by the Author:	25-Jun-2019
Complete List of Authors:	Perego, Paolo; Politecnico di Milano, Design Department Rashid, Rajeeb; The University of Edinburgh Department of Child Life and Health, Department of Child Health Gluud, Christian; Copenhagen Trial Unit (CTU), Center for Clinical Intervention Research Jakobsen, Janus; The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital; Holbaek Sygehus, Department of Cardiology Andreoni, Giuseppe; Politecnico di Milano, Design Dept. Lissau, Inge; Copenhagen University Hospital, Clinical Research Centre
Keywords:	Paediatric endocrinology < DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH, Information technology < BIOTECHNOLOGY & BIOINFORMATICS, PAEDIATRICS, PREVENTIVE MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1 **Mobile health applications for intervention in children with overweight. A protocol for** 2 **systematic review with Trial Sequential Analysis**

3
4
5
6
7
8
9
10 4 Perego P¹, Rashid R², Gluud C³, Jakobsen JC^{3,4,5}, Andreoni G¹, Lissau I⁶
11
12 5

13 14 6 **Affiliations**

15
16 7 ¹Department of Design, Politecnico di Milano, Milan, Italy

17
18 8 ²Department of Child Health, University of Edinburgh, Edinburgh, Scotland

19
20 9 ³Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen
21
22 University Hospital, Copenhagen, Denmark.

23 10
24 11 ⁴Department of Cardiology, Holbæk Hospital, Denmark

25
26 12 ⁵Department of Regional Health Research, The Faculty of Health Sciences, University of Southern
27
28 Denmark
29 13

30 14 ⁶Clinical Research Centre, University Hospital Copenhagen, 2650 Hvidovre, Denmark
31
32
33
34 15

35 36 16 **Correspondance to**

37
38 17 Dr. Inge Lissau

39
40 18 Postal Address: Clinical Research Centre, University Hospital Copenhagen, Hvidovre Kettegaard Alle
41
42 30, DK-2650, Hvidovre, Denmark
43 19

44
45 20 Telephone number: 0045-53881018
46

47 21 E-mail: mail@ingelissau.dk
48
49 22

50
51 23 **Word count** 3174
52
53
54 24
55
56 25
57
58 26
59
60 27

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
54

ABSTRACT

Introduction Overweight in children are increasing worldwide. Innovative smartphone health applications (mHealth apps) have sought to deliver single or multi-component interventions for the management of overweight in children. However, the clinical effects of these apps are poorly explored. This systematic review aims to ascertain the effects of different types of mHealth apps in overweight children.

Methods and analysis We will include randomised clinical trials irrespective of publication type, year, status, or language. The effect of different mHealth apps in interventions to overweight (as defined by Cole et al 2000) children (0-18 years age range) will be compared. We plan to classify apps according to type of intervention, measurement device, coaching and reward system. The following databases will be used: Cochrane Library, Excerpta Medica database (Embase), PsycINFO, PubMed, IEEE Explore and Web of Science, CINAHL and LILACS. Primary outcomes will be body weight, quality of life, and serious adverse event. Secondary outcomes will be Body Mass Index z-score (BMI z-score), self-efficacy, anxiety, depression, and adverse event not considered serious. Study inclusion, data extraction, and bias risk assessment will be conducted independently by at least two authors. We will assess risk of bias through eight domains and control risks of random errors with Trial Sequential Analysis. The quality of the evidence will be assessed using Grading of Recommendations Assessment, Development and Evaluation Tool (GRADE).

Ethics and dissemination As the protocol is for a systematic reviews, we do not include patient data and we do not require ethical approval. This review will be published in a peer-reviewed journal.

PROSPERO registration number CRD42019120266

Keywords Obesity, overweight, children, adolescents, smartphone apps, health apps, mHealth app, management, intervention, treatment

Article summary

Strengths and Limitations of this study

- This review will be the first systematic review to investigate the benefits and harms of mobile health apps in children with overweight and obesity following Cochrane methodology.
- A comprehensive search strategy will be used with a large number of databases searched
- Only Randomised Controlled Trials in children with overweight and obesity will be included
- The review will perform Meta-analysis, Trial Sequential Analysis and use the Grading of Recommendations Assessment, Development and Evaluation Tool
- We expect high heterogeneity across studies which may lead to challenges in performing a Meta-analysis
- It is anticipated that many papers will not provide sufficient details on all variables of interest and will lead to reliance on communication with corresponding authors for additional information

INTRODUCTION

The prevalence of overweight are increasing worldwide among children irrespective of income (1–3). By 2025 more than 260 million children aged 5-17 years may be overweight, including 91 million obese according to data from Global Burden of Disease collaborative for 2000 and 2013 (4,5). International Task Force of Obesity produced age and gender specific cut-off for the definition of overweight and obesity in children (6). Throughout this paper we will use the term overweight for all children with overweight including all levels of obesity.

These trends will have long-term consequences on cardiovascular disease, insulin resistance, type 2 diabetes, and cancer (endometrial, breast and colon), resulting in a significant burden on health services across the world (4). Recently, there has been an exponential growth in connected devices such as smartphones and tablets. supporting the development of new services. A plethora of software applications (apps) running on these devices is appearing on the market (Figure 1). Health apps represent a huge segment which exploit the new paradigm of mHealth – Mobile Health. This

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

84 refers to medicine and public health services supported by mobile devices. mHealth apps are
85 commonly used in disease surveillance, treatment support and for educating children about
86 prevention. However, despite the potential opportunities of mHealth, the main issue of these
87 applications is the ability to engage the users to keep them motivated using the app, an aspect that
88 is even more difficult if the users are young.

89
90 Children are “millennials” and “natively digital” hence mobile technologies are the most relevant and
91 accessible tools for them, even in their health management. In this paper, we combined these two
92 elements to analyse the mutual inter-relationships between the use of mobile systems to counteract
93 overweight in children. Recent Cochrane reviews highlighted the benefits of multi-component
94 interventions over single approach programmes on treating children with overweight. The authors,
95 however, noted the paucity of good quality trials on multi-component interventions (7–9).

96
97 **mHealth apps**

98 Smartphones increase the possibility to interact with people in a more personalised and tailored
99 manner. They enable the building of platforms for adaptive interventions with visually appealing and
100 engaging multimedia modalities which can be adjusted by the user based on their preferences (10).
101 mHealth apps have the potential to support children to achieve and maintain a healthy and
102 sustainable lifestyle by supporting and strengthening their self-regulatory capacities (11,12). They
103 offer potential advantages over traditional face-to-face methods for delivering health-related
104 interventions. These include cost-effective dissemination, real-time data collection and feedback,
105 lowered participant burden, and flexible program tailoring (10).

106
107 No reviews to date have compared the efficacy of different categories of apps for interventions in
108 children with overweight. In addition, whilst previous reviews have commented upon the significant

1
2
3 109 risk of bias in many studies, there has not been a consistency in including control of bias, the play
4
5 110 of chance as well as assessing the quality with GRADE assessment in these reviews (13–22).

6
7 111
8
9
10 112 Nutrition and diet apps represent a popular area of mHealth, offering the possibility of delivering
11
12 113 behavioural change interventions for healthy eating and weight management in a scalable and cost-
13
14 114 effective way. Use of commercial apps for paediatric weight management fail to retain users because
15
16 115 of a lack of theoretical background and evidence-based content. mHealth apps that are more
17
18 116 evidence-based are found less engaging and popular among consumers (23). Approaching the apps
19
20
21 117 development process from a multidisciplinary, expert and user-centred design perspective is more
22
23 118 likely to help overcome these limitations. They may also provide easier adoption and integration
24
25 119 of nutritional education apps within primary and secondary care interventions (24,25).

26
27
28 120
29
30
31 121 Such a process has been transitioned into health game apps where long-term use is dependent on
32
33 122 providing easy and continual gaming access on both smartphones and tablets; offering games that
34
35 123 can be personalised and are adaptable based on the child's interests; and maintaining novelty and
36
37 124 interest in the treatment over time. This framework not only provides a benefit to the children
38
39 125 involved, but also provides user data to the coaches, clinicians, and health researchers involved in
40
41 126 the child's treatment regime (26). In addition, many apps tended to focus either on nutrition or on
42
43 127 physical activity. Very few apps managed to adhere to or deliver a comprehensive overweight
44
45 128 intervention for children due to a failure to support a spectrum of important target behaviours (27).

46
47
48
49
50 129
51
52
53 130 The role of health researchers is therefore to evaluate the evidence base, efficacy, and quality
54
55 131 of different apps to ascertain whether these apps may have a part to play in the management
56
57 132 of childhood overweight. In addition, assessment of the effect of the interventions have not been
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

159

evaluated taking risks of bias, risks of random errors, type of control interventions, as well as the quality of evidence into account (28).

Objective

The objective of this review will be to assess the benefits and harms of different categories of mHealth apps in children with overweight.

METHODS AND ANALYSIS

Criteria for considering studies for this review

Types of studies

Randomised clinical trials irrespective of language, publication status, publication type, or publication year. Eligible studies which are not published in English will be translated using Google translate.

Types of participants

All children whom are overweight, up to 18 years of age. We will also include RCTs which include and children and young adults below the age of 21 years. Children with associated co-morbidities, either physical or psychological secondary to overweight will be included.

Types of intervention

Any type of mHealth intervention using apps. There is no restriction as to how the app delivers the intervention or intervention duration or the type of electronic platform (smartphones, tablets etc.).

Types of outcomes

We will assess all outcomes at two time points:

- End of intervention, as defined by trialist (primary time point of interest)
- Maximum follow up.

Primary outcomes

- Body weight measured in kg.
- Quality of life: as measured by any scale that has been validated for use in the target population (29).
- Proportion of participants with at least one serious adverse event (28).

Secondary outcomes

- BMI z-score
- Self-efficacy: as measured by a scale validated for use in children
- Anxiety
- Depression
- Proportion of participants with at least one adverse event not considered serious

Exploratory outcomes

- Body fat measured by bioimpedance or DEXA, there having been good correlation between total body fat % by bioimpedance DEXA ($r = 0.87$, $P < 0.001$) (30,31)
- Muscle mass (kg) via bioimpedance or DEXA (30,31)
- Individual serious and non-serious adverse events

Primary classification of mHealth apps

mHealth apps for overweight interventions usually target three different strategies - diet, physical activity and behaviour. Apps are mainly targeted to monitor or motivate small improvements such as steps per day, duration and intensity of physical activity or counting calories for nutrition. Indeed, behaviour or lifestyle (which also includes nutrition and physical activity) integrates data and suggests activities to the users in order to motivate them and try to change their behaviour.

Based on these three strategies, the apps can be divided into different categories:

- 187 • Presence of devices
 - 188 ○ Standalone mobile applications without connected devices for data gathering
 - 189 ○ Mobile applications with devices (wearable devices, smart scales, etc.)
- 190 • Coach
 - 191 ○ Mobile applications with a real human coach who interacts with the users (phone calls or
 - 192 messages)
 - 193 ○ Mobile applications with a virtual coach which provides suggestions to the users by means
 - 194 of gathered data;
 - 195 ○ Mobile application without a coach: this app only gathers data and shows them to the
 - 196 users;
- 197 • Intervention (only if app includes a coach)
 - 198 ○ Mobile application with a standard reminder/suggestion, like the standard calendar
 - 199 notification
 - 200 ○ Mobile application with an intelligent reminder/suggestion based on acquired data and
 - 201 habits
 - 202 ○ Mobile application without a direct intervention
- 203 • Reward
 - 204 ○ Mobile application with an intangible reward (virtual coins for in app purchase, emoji)
 - 205 ○ Mobile application with a tangible reward (money or discount coupons (32)
 - 206 ○ Mobile application without a reward.

207 Further app categories can be described based on the connection of the application and how users
208 can download it.

- 209 • Cloud and social connectivity
- 210 • Mobile application connected with the cloud to store and process data;
- 211 • Standalone application without a connection.

212 Table 1 shows this app classification with some examples and scientific papers related to them.

Category	Name of the app	Authors	Year	Paper Title
App with device	Collective Intelligence	Addo et al	2013	Toward collective intelligence for fighting obesity
Standalone	iN Touch	Kim et al	2015	Youth-centred Design and Usage Results of the iN Touch Mobile Self-management Program for Overweight/Obesity
Real (Human)	Personal Wellness Coach	Asselin et al	2005	Implementation and evaluation of the personal wellness coach
Virtual	Move it move it	Frost et al	2012	We Like to Move It Move It!: Motivation and Parasocial Interaction
None	iN Touch	Kim et al	2015	Youth-centred Design and Usage Results of the iN Touch Mobile Self-management Program for Overweight/Obesity
Reminder	Txt2Bfit	Partridge et al	2015	Effectiveness of a mHealth Lifestyle Program With Telephone Support (TXT2Bfit) to Prevent Unhealthy Weight Gain in Young Adults: Randomized Controlled
Smart Suggestion	Teenagers and Digital Coaching	Kettunen et al	2018	Can Sport and Wellness Technology be My Personal Trainer?—Teenagers and Digital Coaching
None	MyFitnessPal	Levinson et al	2017	My Fitness Pal calorie tracker usage in the eating disorders
Intangible	Pegaso Dashboard	Caon et al	2016	PEGASO Companion: A Mobile App to Promote Healthy Lifestyles Among Adolescents
Tangible	Pegaso City	Caon et al	2016	PEGASO Companion: A Mobile App to Promote Healthy Lifestyles Among Adolescents
None	Fitbit for Obese	Yoost et al	2018	The Use of Fitbit Technology Among Rural Obese Adolescents
Connected	Collective Intelligence	Addo et al	2013	Toward collective intelligence for fighting obesity
Standalone	Personal Wellness Coach	Asselin et al	2005	Implementation and evaluation of the personal wellness coach

Table 1 Classification of mhealth apps

1
2
3 216
4
5 217
6
7
8 218
9
10 219
11
12 220
13
14 221
15
16 222
17
18
19 223
20
21 224
22
23 225
24
25 226
26
27
28 227
29
30 228
31
32 229
33
34 230
35
36 231
37
38 232
39
40
41 233
42
43 234
44
45 235
46
47 236
48
49
50 237
51
52 238
53
54 239
55
56 240
57
58
59 241
60
242

Search methods for identification of studies

Electronic searches

We will search the following databases:

- Cochrane Library
- MEDLINE
- Excerpta Medica database (Embase)
- PsycINFO
- IEEE Explore
- Web of Science (SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC)
- CINAHL
- LILACS.

Searching other resources

- ClinicalTrials.gov (<http://www.clinicaltrials.gov/>)
- Google Scholar (<https://scholar.google.com/>)
- European Medicine Agency ([http:// www.ema.europa.eu/ema/](http://www.ema.europa.eu/ema/))
- United States Food and Drug Administration ([ww.fda.gov](http://www.fda.gov))
- Medicines and Healthcare Products Regulatory Agency ([https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory- agency](https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency))
- The World Health Organization (www.who.int/)
- Global Obesity Forum (previously International Association for the study of Obesity) (www.iaso.org)
- European Association for the study of Obesity (EASO) (easo.org)
- ICTRP Search Portal

Keywords used in the search strategy

- Obesity
- Overweight
- Smartphone apps
- Health apps
- m-health app
- Body mass index
- Weight gain
- Weight loss
- Hyperphagia

Preliminary search strategy for MEDLINE is enclosed as Appendix 2.

Data collection and analysis

Selection of studies

The review will following the recommendations in the Cochrane Handbook for Systematic Reviews of Interventions and according to Keus et al and Jakobsen et al (33,34). The analyses will be performed using Review Manager (35) and Trial Sequential Analysis programme (36).

Two authors (RR and PP) will independently screen titles and abstracts. They will retrieve all relevant full text study/publication after which two authors will independently screen the full text in order to identify and record reasons for exclusion of the ineligible studies. We will resolve any disagreement through discussion. Trial selection will be displayed in an adapted flow diagram as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.

Data extraction and management

Data extraction will be performed independently by at least two authors, who will both compare

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

the extracted data. Disagreements will be resolved by a third author. We will assess duplicate publications and companion papers of a trial together to evaluate all available data simultaneously (maximise data extraction, correct bias assessment). Trial authors will be contacted by email to request any additional data which may not have been reported sufficiently or at all in the publication. Review Manager software will be used to extract data.

Assessment of risk of bias in included studies

The risk of bias of every included trial will be evaluated independently by at least two authors In case of any disagreement, discrepancies will be discussed with a third author and resolved by consensus. The risk of bias will be assessed using the Cochrane’s ‘Risk of bias’ assessment tool (37,38) and the Cochrane Effective Practice and Organisation of Care Group’s guidance (38). We will evaluate the methodology in respect of:

- Random sequence generation
- Allocation concealment
- Blinding of participants and treatment providers
- Blinding of outcome assessment
- Incomplete outcome data
- Selective outcome reporting
- For profit bias
- Overall risk of bias

Classification of the trials will follow criteria defined in Attached File 3.

Meta-analysis

Both end-scores and change-from-baseline scores will be used to analyse continuous outcomes. If both end-scores and change-from-baseline scores are reported then only end-scores will be used. If only change-from-baseline scores are reported, these results together with end-scores will be

1.

296 analysed in the same meta-analyses (37). Exploratory outcomes will be analysed using change from
297 baseline scores.

298 Data will be meta-analysed by RevMan 5 statistical software. We will use STATA statistical software
299 (STATA 2015) in case of zero event trials, where RevMan 5 zero event handling is insufficient
300 (39,40).

301 Intervention effects will be assessed by both random-effects model meta-analyses and fixed-effect
302 model meta-analyses (22,36,41), using the more conservative point estimate of the two. Three
303 primary outcomes will be examined with $P \leq 0.025$ being statistically significant. An eight-step
304 procedure will be used to assess if the thresholds for significance are crossed. Five secondary
305 outcomes will be examined with $P \leq 0.017$ being statistically significant. The results of the exploratory
306 outcomes will be considered hypothesis generating only.

307 Analysis of all included studies will be compared to a sensitivity analysis of studies at low risk of bias.
308 If the results are similar, primary conclusions will be based at the time point closest to 12 months
309 on the overall analysis. If the results differ, primary conclusions will be based on studies with a low
310 risk of bias.

311 A table describing the types of serious adverse events in each trial will be provided.

312

313 Trial Sequential Analysis

314 Traditional meta-analysis runs the risk of random errors due to sparse data and repetitive testing of
315 accumulating data when updating reviews. Trial Sequential Analysis will thus be used to analyse the
316 outcomes in order to calculate the required information size and control the risks of type I errors
317 and type II errors (21,22,40).

318

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For continuous outcomes, Trial Sequential Analysis will use the observed SD, a mean difference of the observed SD/2, an alpha of 2.5% for the three primary outcomes, an alpha of 1.67% for the five secondary outcomes and a beta of 10%, with adjustment for observed diversity (42,43). Mean differences (MDs) and the standardised mean difference will be expressed with 95% confidence intervals (CI) for continuous outcomes, as well as the Trial Sequential Analysis adjusted CIs for MDs.

For dichotomous outcomes, Trial Sequential Analysis will use the proportion of participants with an outcome in the control group, a relative risk reduction of 20%, an alpha of 2.5% for primary outcomes, an alpha of 1.67% for secondary outcomes, and a beta of 10%, with adjustment for observed diversity. We will calculate risk ratios with 95% CI for dichotomous outcomes, as well as Trial Sequential Analysis adjusted CIs.

Subgroup analyses

Subgroup analysis when analysing the primary outcomes will be performed as follows:

- Trials at high risk of bias trials compared to trials at low risk of bias trials.
- Trial stratified according to experimental interventions.
- Trial stratified according to the control interventions.
- Complexity: trials with participants with no co-morbidities compared to trials with participants pre-existing co-morbidities.
- Trials in which the experimental intervention was evaluated by either the parents or the child after the treatment sessions had been delivered compared to trials in which the experimental intervention was not evaluated by either the parents or the child after the treatment sessions had been delivered.

We will use the formal test for subgroup interactions in Review Manager (35).

Sensitivity analysis

To assess the potential impact of bias, we will perform a sensitivity analysis to exclude trials at overall 'high risk of bias'.

To assess the potential impact of the missing data for dichotomous outcomes, we will perform the following sensitivity analyses:

- 'Best-worst-case' scenario: we will assume that all participants lost to follow-up in the experimental group had no serious adverse events, including not developing any psychiatric disease such as an eating disorder.
- Worst-best case scenario: all dropouts/participants lost from the experimental group, but none from the control group experienced the outcome, including all randomised participants in the denominator.

Statistical heterogeneity will be assessed by visual inspection of the forest plots and I^2 statistic values (33). Underlying reasons behind statistical heterogeneity in meta-analyses will be investigated by assessing trial characteristics.

Summary of findings table

A summary of findings table using each of the prespecified primary and secondary outcomes will be reported using the GRADE considerations for studies which contribute data to the meta-analyses for the prespecified outcomes (28,33,52–57,44–51). Methods and recommendations described in Chapter 8 (Section 8.5) and Chapter 12 of the *Cochrane Handbook for Systematic Reviews of Interventions* (58) will be followed using GRADEpro software.

DISCUSSION

This review aims to provide evidence and compare the beneficial and harmful effects of different categories of mHealth apps for children with overweight. Currently, there are no systematic reviews which compare the effects of mHealth apps to interventions in children with overweight. Previous systematic reviews in children have considered the efficacy of mobile health technologies more

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

broadly in the role of weight management (57), but none have provided comprehensive coverage of the benefits and harms of mHealth apps. Hence, this evidence will hopefully help children, their parents, and health professionals to make informed treatment decisions. This review will also highlight any gaps in the evidence base of such interventions which will help to shape the development and optimization of future potential interventions.

ETHICS AND DISSEMINATION

Acknowledgements We would like to thank Sarah Louise Klingenberg, Information Specialist at the Copenhagen Trial Unit, Centre for Clinical Intervention Research for her guidance and assistance on developing search methods keywords for search strategies.

Author contributions IL, RR, PP, GA, CG and JCJ wrote the first draft of the protocol. PP, RR, IL, GA, JCJ and CG have revised the protocol. All authors read and approved the manuscript. IL is the guarantor for the review.

Funding This research received no specific grant from any funding agency.

Availability of data and materials Not applicable.

Competing interests None known.

Patient consent Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. *Int J Pediatr Obes*. 2007/09/29. 2006;1(1):11–25.
2. Lobstein T. The prevention of obesity in children. *Pediatr Endocrinol Rev*. 2006/01/31. 2004;1 Suppl 3:471–5.
3. de Onis M, Blossner M, Borghi E. Global prevalence and trends of overweight and obesity among preschool children. *Am J Clin Nutr*. 2010/09/24. 2010;92(5):1257–64.
4. Organisation WH. COSI: Childhood Obesity Surveillance Initiative. Copenhagen: WHO; 2018.
5. Organisation WH. Obesity and Overweight [Internet]. Copenhagen; 2016. Available from: <http://www.who.int/mediacentre/factsheets/fs311/en/>
6. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. *BMJ*. 2000/05/08. 2000;320(7244):1240–3.
7. Colquitt JL, Loveman E, O'Malley C, Azevedo LB, Mead E, Al-Khudairy L, et al. Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in preschool children up to the age of 6 years. *Cochrane Database Syst Rev*. 2016/03/11. 2016;3:CD012105.
8. Al-Khudairy L, Loveman E, Colquitt JL, Mead E, Johnson RE, Fraser H, et al. Diet, physical activity and behavioural interventions for the treatment of overweight or obese adolescents aged 12 to 17 years. *Cochrane Database Syst Rev*. 2017;6:CD012691.
9. Mead E, Brown T, Rees K, Azevedo LB, Whittaker V, Jones D, et al. Diet, physical activity and behavioural interventions for the treatment of overweight or obese children from the age of 6 to 11 years. *Cochrane Database Syst Rev*. 2017/06/24. 2017;6:CD012651.
10. Tate EB, Spruijt-Metz D, O'Reilly G, Jordan-Marsh M, Gotsis M, Pentz MA, et al. mHealth approaches to child obesity prevention: successes, unique challenges, and next directions. *Transl Behav Med*. 2013/12/03. 2013;3(4):406–15.
11. Anderson J, Kamphorst B. Ethics of e-coaching: Implications of employing pervasive computing to promote healthy and sustainable lifestyles. 2014. 351–356 p.
12. Baroni I, Nalin M, Coti Zelati M, Oleari E, Sanna A. Designing motivational robot: How robots might motivate children to eat fruits and vegetables. Vol. 2014. 2014.
13. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. *Ann Intern Med*. 2001/12/04. 2001;135(11):982–9.
14. Schunemann HJ, Wiercioch W, Brozek J, Etzeandía-Ikobaltzeta I, Mustafa RA, Manja V, et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. *J Clin Epidemiol*. 2016/10/08. 2017;81:101–10.
15. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised, controlled trials. *Ann Intern Med* [Internet]. 2012;157. Available from: <https://doi.org/10.7326/0003-4819-157-6-201209180-00537>

- 1
2
3 441 16. Savovic J, Jones H, Altman D, Harris R, Juni P, Pildal J, et al. Influence of reported study
4 442 design characteristics on intervention effect estimates from randomised controlled trials:
5 443 combined analysis of meta-epidemiological studies. *Heal Technol Assess*. 2012/09/20.
6 444 2012;16(35):1–82.
- 8 445 17. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of
9 446 methodological quality associated with estimates of treatment effects in controlled trials.
10 447 *Jama*. 1995/02/01. 1995;273(5):408–12.
- 12 448 18. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias
13 449 in treatment effect estimates in controlled trials with different interventions and outcomes:
14 450 meta-epidemiological study. *Bmj*. 2008/03/05. 2008;336(7644):601–5.
- 16 451 19. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research
17 452 outcome. *Cochrane Database Syst Rev*. 2012/12/14. 2012;12:Mr000033.
- 19 453 20. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of
20 454 randomised trials affect estimates of intervention efficacy reported in meta-analyses?
21 455 *Lancet*. 1998/09/24. 1998;352(9128):609–13.
- 23 456 21. Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with
24 457 meta-analysis. *BMC Med Res Methodol* [Internet]. 2017;17(1):39. Available from:
25 458 <https://doi.org/10.1186/s12874-017-0315-7>
- 27 459 22. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by
28 460 quantifying diversity in random-effects model meta-analyses. *BMC Med Res Methodol*.
29 461 2010/01/01. 2009;9:86.
- 31 462 23. Boulos MN, Brewer AC, Karimkhani C, Buller DB, Dellavalle RP. Mobile medical and health
32 463 apps: state of the art, concerns, regulatory control and certification. *Online J Public Heal Inf*.
33 464 2014/04/01. 2014;5(3):229.
- 35 465 24. Gabrielli S, Dianti M, Maimone R, Betta M, Filippi L, Ghezzi M, et al. Design of a Mobile App
36 466 for Nutrition Education (TreC-LifeStyle) and Formative Evaluation With Families of
37 467 Overweight Children. *JMIR Mhealth Uhealth*. 2017/04/15. 2017;5(4):e48.
- 39 468 25. Kim K, Christine H, Young E, Sabee C. Youth-centered design and usage results of the iN
40 469 Touch mobile self-management program for overweight/obesity. Vol. 19. 2015.
- 42 470 26. Watters C, Author M, Abouzied A, Cox A, Kellar M, Kharrazi H, et al. Extending the Use of
43 471 Games in Health Care. Vol. 5. 2006.
- 45 472 27. Breton ER, Fuemmeler BF, Abrams LC. Weight loss-there is an app for that! But does it
46 473 adhere to evidence-informed practices? *Transl Behav Med*. 2011/12/01. 2011;1(4):523–9.
- 48 474 28. Garattini S, Jakobsen JC, Wetterslev J, Bertele V, Banzi R, Rath A, et al. Evidence-based
49 475 clinical practice: Overview of threats to the validity of evidence and how to minimise them.
50 476 *Eur J Intern Med*. 2016/05/11. 2016;32:13–21.
- 52 477 29. Ahuja B, Klassen AF, Satz R, Malhotra N, Tsangaris E, Ventresca M, et al. A review of
53 478 patient-reported outcomes for children and adolescents with obesity. *Qual Life Res*.
54 479 2013/06/27. 2014;23(3):759–70.
- 56 480 30. A. B. Social foundations of thought and action: A social cognitive theory. Englewood Cliffs:
57 481 Prentice-Hall; 1986.
- 59 482 31. Murtagh J, Dixey R, Rudolf M. A qualitative investigation into the levers and barriers to

- weight loss in children: opinions of obese children. *Arch Dis Child*. 2006/07/06. 2006;91(11):920–3.
32. Pedersen, Carmen and AH. Smart Technology for Health and Well-being. *J Fam Consum Sci*. 2018;110(2):55–6.
 33. Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. *BMC Med Res Methodol*. 2014/11/25. 2014;14:120.
 34. Keus F, Wetterslev J, Gluud C, Laarhoven CJ. Evidence at a glance: error matrix approach for over-viewing available evidence. *BMC Med Res Methodol* [Internet]. 2010;10. Available from: <https://doi.org/10.1186/1471-2288-10-90>
 35. Collaboration C. Review Manager. Copenhagen: Nordic Cochrane Centre; 2014.
 36. Thorlund K, Wetterslev J, Brok J, Imberger G et al EJ. User manual for trial sequential analysis (TSA). [Internet]. 2011. Available from: www.ctu.dk/tsa
 37. Davey J, Turner RM, Clarke MJ, Higgins JP. Characteristics of meta-analyses and their component studies in the Cochrane Database of Systematic Reviews: a cross-sectional, descriptive analysis. *BMC Med Res Methodol*. 2011/11/26. 2011;11:160.
 38. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ*. 2011/02/12. 2011;342:d549.
 39. Demets DL. Methods for combining randomized clinical trials: strengths and limitations. *Stat Med*. 1987/04/01. 1987;6(3):341–50.
 40. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. *J Clin Epidemiol* [Internet]. 2008;61. Available from: <https://doi.org/10.1016/j.jclinepi.2007.03.013>
 41. Keus F, Wetterslev J, Gluud C, Gooszen HG, van Laarhoven CJ. Trial sequential analyses of meta-analyses of complications in laparoscopic vs. small-incision cholecystectomy: more randomized patients are needed. *J Clin Epidemiol*. 2009/12/17. 2010;63(3):246–56.
 42. Proposal for a good clinical practice directive. *Bull Med Ethics*. 2001/10/20. 1998;No. 135:6–11.
 43. StataCorp. StataCorp Statistical Software [Internet]. Release 14. College Station: StataCorp LP; 2014. Available from: <http://www.stata.com>
 44. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008/04/26. 2008;336(7650):924–6.
 45. Schunemann HJ, Best D, Vist G, Oxman AD. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. *Cmaj*. 2003/10/01. 2003;169(7):677–80.
 46. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. *J Clin Epidemiol*. 2010/12/28. 2011;64(4):380–2.
 47. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. *BMJ*. 2004/06/19. 2004;328(7454):1490.

1
2
3 524 48. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1.
4 525 Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol.
5 526 2011/01/05. 2011;64(4):383–94.
6
7 527 49. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2.
8 528 Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011/01/05.
9 529 2011;64(4):395–400.
10
11 530 50. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines:
12 531 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol.
13 532 2011/01/21. 2011;64(4):407–15.
14
15 533 51. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5.
16 534 Rating the quality of evidence--publication bias. J Clin Epidemiol. 2011/08/02.
17 535 2011;64(12):1277–82.
18
19 536 52. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines:
20 537 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol. 2011/08/02.
21 538 2011;64(12):1294–302.
22
23 539 53. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines:
24 540 8. Rating the quality of evidence--indirectness. J Clin Epidemiol. 2011/08/02.
25 541 2011;64(12):1303–10.
26
27 542 54. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE
28 543 guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol. 2011/08/02.
29 544 2011;64(12):1311–6.
30
31 545 55. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE
32 546 guidelines: 11. Making an overall rating of confidence in effect estimates for a single
33 547 outcome and for all outcomes. J Clin Epidemiol. 2012/05/01. 2013;66(2):151–7.
34
35 548 56. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12.
36 549 Preparing summary of findings tables-binary outcomes. J Clin Epidemiol. 2012/05/23.
37 550 2013;66(2):158–72.
38
39 551 57. Darling KE, Sato AF. Systematic Review and Meta-Analysis Examining the Effectiveness of
40 552 Mobile Health Technologies in Using Self-Monitoring for Pediatric Weight Management. Child
41 553 Obes. 2017/05/05. 2017;13(5):347–55.
42
43 554 58. Collaboration TC, Green JPTH and S. Cochrane Handbook for Systematic Reviews of
44 555 Interventions . Cochrane Book Series . Wiley-Blackwell; 2008.
45
46
47
48
49

50 557 **Appendices**


- 51
52 558 Additional File 1: Prisma-P+ checklist.
53
54 559 Additional File 2: Preliminary search strategy for MEDLINE (Ovid).
55
56 560 Additional File 3: Classification of randomised trials at low and high risk of bias.
57
58
59
60

563 **Images legends**

564 Figure 1: Overweight and obesity prevalence values based on WHO definition /(%) - COSI 2015-2017

565 (4)

For peer review only



Overweight and obesity prevalence values based on WHO definition - COSI 2015-2017 (4)

Reporting checklist for protocol of a systematic review.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preorting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

Reporting Item			Page Number
Title			
Identification	#1a	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	n/a
Registration			
	#2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors			
Contact	#3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	#3b	Describe contributions of protocol authors and identify the guarantor of the review	15

Amendments

	#4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	n/a
Support			
Sources	#5a	Indicate sources of financial or other support for the review	15
Sponsor	#5b	Provide name for the review funder and / or sponsor	n/a
Role of sponsor or funder	#5c	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	n/a
Introduction			
Rationale	#6	Describe the rationale for the review in the context of what is already known	2
Objectives	#7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	6
Methods			
Eligibility criteria	#8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6
Information sources	#9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	9
Search strategy	#10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	10
Study records - data management	#11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	11
Study records - selection process	#11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	10
Study records - data collection process	#11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for	10

		obtaining and confirming data from investigators	
1			
2	Data items	#12 List and define all variables for which data will be sought (such as	7
3		PICO items, funding sources), any pre-planned data assumptions and	
4		simplifications	
5			
6			
7			
8	Outcomes and	#13 List and define all outcomes for which data will be sought, including	7
9	prioritization	prioritization of main and additional outcomes, with rationale	
10			
11	Risk of bias in	#14 Describe anticipated methods for assessing risk of bias of individual	11
12	individual studies	studies, including whether this will be done at the outcome or study	
13		level, or both; state how this information will be used in data synthesis	
14			
15			
16			
17	Data synthesis	#15a Describe criteria under which study data will be quantitatively	14
18		synthesised	
19			
20			
21	Data synthesis	#15b If data are appropriate for quantitative synthesis, describe planned	14
22		summary measures, methods of handling data and methods of	
23		combining data from studies, including any planned exploration of	
24		consistency (such as I ² , Kendall's τ)	
25			
26			
27	Data synthesis	#15c Describe any proposed additional analyses (such as sensitivity or	11
28		subgroup analyses, meta-regression)	
29			
30			
31	Data synthesis	#15d If quantitative synthesis is not appropriate, describe the type of	n/a
32		summary planned	
33			
34			
35	Meta-bias(es)	#16 Specify any planned assessment of meta-bias(es) (such as publication	12
36		bias across studies, selective reporting within studies)	
37			
38			
39	Confidence in	#17 Describe how the strength of the body of evidence will be assessed	14
40	cumulative	(such as GRADE)	
41	evidence		
42			
43			

The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. This checklist was completed on 24. June 2019 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

Search strategies for
Apps vs no apps
Preliminary searches performed 23 April 2019

Total number of records identified: 4494 records
Number of duplicates excluded: 743 records
Number of records in final list: 3751 records

Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (2019, Issue 4) (546 hits)

- #1 MeSH descriptor: [Obesity] explode all trees
- #2 MeSH descriptor: [Hyperphagia] explode all trees
- #3 MeSH descriptor: [Body Mass Index] explode all trees
- #4 MeSH descriptor: [Weight Gain] explode all trees
- #5 MeSH descriptor: [Weight Loss] explode all trees
- #6 MeSH descriptor: [Anti-Obesity Agents] 1 tree(s) exploded
- #7 (Pickwick* syndrom* or Prader willi syndrom* or obes* or adipos* or overweight* or 'over weight*' or overeat* or 'over eat*' or 'over feed*' or overfeed* or binge eating disorder* or 'fat overload' syndrom* or (weight and (gain or cycling or reduc* or loss or losing or maint* or decreas* or watch* or diet* or control*)))ti,ab
- #8 #1 or #2 or #3 or #4 or #5 or #6 or #7
- #9 MeSH descriptor: [Mobile Applications] explode all trees
- #10 ((mobile or smartphone or telephone or virtual or digital or wellness or medical or dietary or physical activity or intervention or treatment or weight or calorie) and (app or coach or tracker))
- #11 (m*health or mobile health or p*health or personal health or 'in touch' or txt2bfit or pegaso or fitbit or collective intelligence or 'move it' or myfitnesspal)
- #12 #9 or #10 or #11
- #13 #8 and #12

MEDLINE Ovid (1946 to April 2019) (510 hits)

- 1. exp Obesity/
- 2. exp Hyperphagia/
- 3. exp body mass index/
- 4. exp Weight Gain/
- 5. exp Weight Loss/
- 6. exp Anti-Obesity Agents/
- 7. (Pickwick* syndrom* or Prader willi syndrom* or obes* or adipos* or overweight* or 'over weight*' or overeat* or 'over eat*' or 'over feed*' or overfeed* or binge eating disorder* or 'fat overload' syndrom* or (weight and (gain or cycling or reduc* or loss or losing or maint* or decreas* or watch* or diet* or control*)))ti,ab.
- 8. 1 or 2 or 3 or 4 or 5 or 6 or 7
- 9. exp Mobile Applications/
- 10. ((mobile or smartphone or telephone or virtual or digital or wellness or medical or dietary or physical activity or intervention or treatment or weight or calorie) and (app or coach or tracker)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
- 11. (m*health or mobile health or p*health or personal health or 'in touch' or txt2bfit or pegaso or fitbit or collective intelligence or 'move it' or myfitnesspal).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
- 12. 9 or 10 or 11
- 13. 8 and 12
- 14. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
- 15. 13 and 14

Embase Ovid (1974 to April 2019) (802 hits)

- 1. exp obesity/
- 2. exp hyperphagia/

3. exp body mass/
4. exp body weight gain/
5. exp body weight loss/
6. exp antiobesity agent/
7. (Pickwick* syndrom* or Prader willi syndrom* or obes* or adipos* or overweight* or 'over weight*' or overeat* or 'over eat*' or 'over feed*' or overfeed* or binge eating disorder* or 'fat overload' syndrom* or (weight and (gain or cycling or reduc* or loss or losing or maint* or decreas* or watch* or diet* or control*))) .ti,ab.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp mobile application/
10. ((mobile or smartphone or telephone or virtual or digital or wellness or medical or dietary or physical activity or intervention or treatment or weight or calorie) and (app or coach or tracker)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
11. (m*health or mobile health or p*health or personal health or 'in touch' or txt2bfit or pegaso or fitbit or collective intelligence or 'move it' or myfitnesspal).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
12. 9 or 10 or 11
13. 8 and 12
14. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
15. 13 and 14

LILACS (Bireme; 1982 to April 2019) (24 hits)

(Pickwick\$ syndrom\$ or Prader willi syndrom\$ or obes\$ or adipos\$ or overweight\$ or 'over weight\$' or overeat\$ or 'over eat\$' or 'over feed\$' or overfeed\$ or binge eating disorder\$ or 'fat overload' syndrom\$ or (weight and (gain or cycling or reduc\$ or loss or losing or maint\$ or decreas\$ or watch\$ or diet\$ or control\$))) [Words] and (((mobile or smartphone or telephone or virtual or digital or wellness or medical or dietary or physical activity or intervention or treatment or weight or calorie) and (app or coach or tracker)) or (m\$health or mobile health or p\$health or personal health or 'in touch' or txt2bfit or pegaso or fitbit or collective intelligence or 'move it' or myfitnesspal)) [Words]

Science Citation Index Expanded (SCI-EXPANDED) (1900 to April 2019), Social Sciences Citation Index (SSCI) (1956 to April 2019), Arts & Humanities Citation Index (A&HCI) (1975 to April 2019), Conference Proceedings Citation Index- Science (CPCI-S) (1990- April 2019), Conference Proceedings Citation Index- Social Science & Humanities (CPCI-SSH) (1990- April 2019), Emerging Sources Citation Index (ESCI) (2015 to April 2019), Web of Science Core Collection: Chemical Indexes Current Chemical Reactions (CCR-EXPANDED) (1986 to April 2019), Index Chemicus (IC) (1993 to April 2019) (Web of Science) (2612 hits)

#7 #6 AND #5

#6 TS=(random* or blind* or placebo* or meta-analys*)

#5 #4 AND #1

#4 #3 OR #2

#3 TS=(m*health or mobile health or p*health or personal health or 'in touch' or txt2bfit or pegaso or fitbit or collective intelligence or 'move it' or myfitnesspal)

#2 TS=((mobile or smartphone or telephone or virtual or digital or wellness or medical or dietary or physical activity or intervention or treatment or weight or calorie) and (app or coach or tracker))

#1 TS=(Pickwick* syndrom* or Prader willi syndrom* or obes* or adipos* or overweight* or 'over weight*' or overeat* or 'over eat*' or 'over feed*' or overfeed* or binge eating disorder* or 'fat overload' syndrom* or (weight and (gain or cycling or reduc* or loss or losing or maint* or decreas* or watch* or diet* or control*)))

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Assessment of risk of bias in included studies

Random sequence generation

Low risk: If sequence generation was achieved using computer random number generator or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were also considered adequate if performed by an independent adjudicator.

Unclear risk: If the method of randomisation was not specified, but the trial was still presented as being randomised.

High risk: If the allocation sequence is not randomised or only quasi-randomised. These trials will be excluded.

Allocation concealment

Low risk: If the allocation of patients was performed by a central independent unit, on-site locked computer or identical-looking numbered sealed envelopes.

Uncertain risk: If the trial was classified as randomised but the allocation concealment process was not described.

High risk: If the allocation sequence was familiar to the investigators who assigned participants.

Blinding of participants and treatment providers

Low risk: If the participants and the treatment providers were blinded to intervention allocation and this was described.

Uncertain risk: If the procedure of blinding was insufficiently described.

High risk: If blinding of participants and the treatment providers was not performed.

Blinding of outcome assessment

Low risk of bias: If it was mentioned that outcome assessors were blinded and this was described.

Uncertain risk of bias: If it was not mentioned if the outcome assessors in the trial were blinded or the extent of blinding was insufficiently described.

High risk of bias: If no blinding or incomplete blinding of outcome assessors was performed.

Incomplete outcome data

Low risk of bias: If missing data were unlikely to make treatment effects depart from plausible values. This could be either (1) there were no drop-outs or withdrawals for all outcomes, or (2) the numbers and reasons for the withdrawals and drop-outs for all outcomes were clearly stated and could be described as being similar to both groups. Generally, the trial is judged as at a low risk of bias due to incomplete outcome data if drop-outs are less than 5%. However, the 5% cut-off is not definitive.

Uncertain risk of bias: If there was insufficient information to assess whether missing data were likely to induce bias on the results.

High risk of bias: If the results were likely to be biased due to missing data either because the pattern of drop-outs could be described as being different in the two intervention groups or the trial used improper methods in dealing with the missing data (e.g. last observation carried forward).

Selective outcome reporting

Low risk of bias: If a protocol was published before or at the time the trial was begun and the outcomes specified in the protocol were reported on. If there is no protocol

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

or the protocol was published after the trial has begun, reporting of serious adverse events will grant the trial a grade of low risk of bias.

Uncertain risk of bias: If no protocol was published and the outcome of serious adverse events were not reported on.

High risk of bias: If the outcomes in the protocol were not reported on.

Other risks of bias

Low risk of bias: If the trial appears to be free of other components (for example, academic bias or for-profit bias) that could put it at risk of bias.

Unclear risk of bias: If the trial may or may not be free of other components that could put it at risk of bias.

High risk of bias: If there are other factors in the trial that could put it at risk of bias (for example, authors conducted trials on the same topic, for-profit bias, etc.).

Overall risk of bias

Low risk of bias: The trial will be classified as overall 'low risk of bias' only if all of the bias domains described in the above paragraphs are classified as 'low risk of bias'.

High risk of bias: The trial will be classified as 'high risk of bias' if any of the bias risk domains described in the above are classified as 'unclear' or 'high risk of bias'.

We will assess the domains 'blinding of outcome assessment', 'incomplete outcome data', and 'selective outcome reporting' for each outcome result. Thus, we can assess the bias risk for each outcome assessed in addition to each trial. Our primary conclusions will be based on the results of our primary outcome results with overall low risk of bias. Both our primary and secondary conclusions will be presented in the summary of findings tables.

BMJ Open

Mobile health applications for intervention in children and adolescent with overweight. A protocol for systematic review with meta analysis and Trial Sequential Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032570.R1
Article Type:	Protocol
Date Submitted by the Author:	01-Apr-2020
Complete List of Authors:	Perego, Paolo; Politecnico di Milano, Design Department Rashid, Rajeeb; The University of Edinburgh Department of Child Life and Health, Department of Child Health Gluud, Christian; Copenhagen Trial Unit (CTU), Center for Clinical Intervention Research Jakobsen, Janus; The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital; Holbaek Sygehus, Department of Cardiology Andreoni, Giuseppe; Politecnico di Milano, Design Dept. Lissau, Inge; University Hospital Copenhagen, Clinical Research Centre
Primary Subject Heading:	Paediatrics
Secondary Subject Heading:	Global health, Paediatrics, Public health
Keywords:	Paediatric endocrinology < DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH, Information technology < BIOTECHNOLOGY & BIOINFORMATICS, PAEDIATRICS, PREVENTIVE MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Mobile health applications for intervention in children and adolescent with overweight.
A protocol for systematic review with meta analysis and Trial Sequential Analysis

Perego P¹, Rashid R², Gluud C³, Jakobsen JC^{3,4,5}, Andreoni G¹, Lissau I^{6,7}

Affiliations

¹Department of Design, Politecnico di Milano, Milan, Italy

²Department of Child Health, University of Edinburgh, Edinburgh, Scotland

³Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

⁴Department of Cardiology, Holbæk Hospital, Denmark

⁵Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark

⁶Clinical Research Centre, University Hospital Copenhagen, 2650 Hvidovre, Denmark

⁷Department of Clinical Sciences, Faculty of Medicine, University of Lund, Lund, Sweden.

Correspondance to

Dr. Inge Lissau

Postal Address: Clinical Research Centre, University Hospital Copenhagen, Hvidovre Kettegaard Alle 30, DK-2650, Hvidovre, Denmark

Telephone number: 0045-53881018

E-mail: info@ingelissau.dk

Word count 3401

1
2
3 28
4
5 29
6
7 30
8
9 31
10
11 32
12
13 33
14
15 34
16
17 35
18
19
20
21 36
22
23
24 37
25
26 38
27
28 39
29
30 40
31
32 41
33
34 42
35
36 43
37
38 44
39
40 45
41
42 46
43
44 47
45
46 48
47
48 49
49
50 50
51
52 51
53
54 52
55
56 53
57
58
59
60

ABSTRACT

Introduction Overweight in children are increasing worldwide. Innovative smartphone health applications (mHealth apps) have sought to deliver single or multi-component interventions for the management of overweight in children. However, the clinical effects of these apps are poorly explored. The objective of the review will be to compare the benefits and harms of different categories of mHealth apps for intervention of overweight in children.

Methods and analysis We will include randomised clinical trials irrespective of publication type, year, status, or language. Children and adolescents between 0-18 years will be referred to as children in the remaining part of the paper. Children with all degrees of overweight included obesity and morbidly obese in the remaining part of the paper will be referred to as overweight. We plan to classify different apps according to type of intervention, measurement device, coaching and reward system. The following databases will be used: Cochrane Library, Excerpta Medica database (Embase), PsycINFO, PubMed, IEEE Explore and Web of Science, CINAHL and LILACS. Primary outcomes will be body mass index z-score (BMI z-score), quality of life, and serious adverse event. Secondary outcomes will be body weight, self-efficacy, anxiety, depression, and adverse event not considered serious. Study inclusion, data extraction, and bias risk assessment will be conducted independently by at least two authors. We will assess risk of bias through eight domains and control risks of random errors with Trial Sequential Analysis. The quality of the evidence will be assessed using Grading of Recommendations Assessment, Development and Evaluation Tool (GRADE).

Ethics and dissemination As the protocol is for a systematic reviews, we do not include patient data and we do not require ethical approval. This review will be published in a peer-reviewed journal.

PROSPERO registration number CRD42019120266

Keywords Obesity, overweight, children, adolescents, smartphone apps, health apps, mHealth app, management, intervention, treatment

ARTICLE SUMMARY

Strengths and Limitations of this study

- This review aims to be the first systematic review to investigate the benefits and harms of mobile health app interventions in children with overweight following Cochrane guidelines.
- A comprehensive search strategy will be used with a large number of databases searched, and only Randomised Controlled Trials in children with overweight will be included.
- The review will perform meta-analysis, Trial Sequential Analysis and use the Grading of Recommendations Assessment, Development and Evaluation Tool.
- We expect high heterogeneity across studies which may lead to challenges in performing a Meta-analysis.
- It is anticipated that many papers will not provide sufficient details on all variables of interest and will lead to reliance on communication with corresponding authors for additional information.

INTRODUCTION

The prevalence of overweight are increasing worldwide among children irrespective of socio-economic status (1–3). By 2025 more than 260 million children aged 5-17 years may be overweight, including 91 million obese according to data from Global Burden of Disease collaborative for 2000 and 2013 (4,5). International Task Force of Obesity produced age and gender specific cut-off for the definition of overweight and obesity in children (6). Throughout this paper we will use the term overweight for all children with overweight including all levels of obesity.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

82 These trends of increasing overweight will have long-term consequences on cardiovascular disease,
83 insulin resistance, type 2 diabetes, and cancer (endometrial, breast and colon), resulting in a
84 significant burden on health services across the world (4). Recently, there has been an exponential
85 growth in connected devices such as smartphones and tablets. supporting the development of new
86 services. A plethora of software application (apps) running on these devices is appearing on the
87 market (Figure 1). Health apps represent a huge segment which exploit the new paradigm of
88 mHealth – Mobile Health. This refers to medicine and public health services supported by mobile
89 devices. mHealth apps are commonly used in disease surveillance, treatment support and for
90 educating children about prevention. However, despite the potential opportunities of mHealth, the
91 main issue of these applications is the ability to engage the users to keep them motivated using the
92 app, an aspect that is even more difficult if the users are young (7).

93
94 Children are “millennials” and “natively digital” hence mobile technologies are potentially relevant
95 and accessible tools for them, even in their health management. In this paper, we combined these
96 two elements to analyse the mutual inter-relationships between the use of mobile systems to
97 counteract overweight in children. Recent Cochrane reviews highlighted the benefits of multi-
98 component interventions over single approach programmes on treating children with overweight.
99 The authors, however, noted the paucity of good quality trials on multi-component interventions (8–
100 10).

101
102 **mHealth apps**

103 Smartphones increase the possibility to interact with people in a more personalised and tailored
104 manner. They enable the building of platforms for adaptive interventions with visually appealing and
105 engaging multimedia modalities which can be adjusted by the user based on their preferences (11).
106 mHealth apps have the ability to support children to achieve and maintain a healthy and sustainable
107 lifestyle by supporting and strengthening their self-regulatory capacities (12,13). They offer potential
108 advantages over traditional face-to-face methods for delivering health-related interventions (14–

17). These include cost-effective dissemination, real-time data collection and feedback, lowered participant burden, and flexible program tailoring (11).

No reviews to date, to our best knowledge, have specifically compared the efficacy of different categories of apps for interventions in children with overweight. In addition, whilst previous reviews have commented upon the significant risk of bias in many studies, there has not been a consistency in including control of bias, the play of chance and assessing the quality with GRADE assessment in these reviews (18–27).

Nutrition and diet apps represent a popular area of mHealth, offering the possibility of delivering behavioural change interventions for healthy eating and weight management in a scalable and cost-effective way. Use of commercial apps for paediatric weight management fail to retain users because of a lack of theoretical background and evidence-based content. mHealth apps that are more evidence-based are often found less engaging and popular among consumers (28). Approaching the apps development process from a multidisciplinary, expert and user-centred design perspective is more likely to help overcome these limitations. They may also provide easier adoption and integration of nutritional education apps within primary and secondary care interventions (29,30).

Such a process has been transitioned into health game apps where long-term use is dependent on providing easy and continual gaming access on both smartphones and tablets; offer games that can be personalised and are adaptable based on the child's interests; and maintain novelty and interest in the treatment over time (31). This framework not only provides a benefit to the children involved, but also provides user data to the coaches, clinicians, and health researchers involved in the child's treatment regime (32). In addition, whilst many apps tended to focus either on nutrition or on physical activity, very few apps managed to adhere to or deliver a comprehensive overweight intervention for children due to a failure to support a spectrum of important target behaviours (33).

1
2
3 135
4
5
6 136
7
8 137
9
10 138
11
12
13 139
14
15 140
16
17 141
18
19 142
20
21
22 143
23
24 144
25
26
27 145
28
29 146
30
31 147
32
33
34 148
35
36 149
37
38 150
39
40 151
41
42 152
43
44
45 153
46
47 154
48
49 155
50
51 156
52
53 157
54
55
56 158
57
58 159
59
60 160

The role of health researchers is therefore to evaluate the evidence base, efficacy, and quality of different apps to ascertain whether these apps may have a part to play in the management of childhood overweight. In addition, assessment of the effect of the interventions have not been evaluated taking risks of bias, risks of random errors, type of control interventions, as well as the quality of evidence into account (34).

Objective

The objective of the review will be to compare the benefits and harms of different categories of mHealth apps for intervention of overweight in children.

METHODS AND ANALYSIS

Criteria for considering studies for this review

Types of studies

Randomised clinical trials irrespective of language, publication status, publication type, or publication year up to April 2020. Eligible studies which are not published in English will be translated using Google translate. Authors will be contacted to check if an English translation is available or to clarify any queries.

Types of participants

All children who are overweight (including all levels of obesity) up to 18 years of age (as defined earlier). We will also include randomised clinical trials which include children and young adults below the age of 21 years. Children with associated co-morbidities, either physical or psychological secondary to overweight and obesity will be included. Children with causes of overweight due to medication such as steroids, or genetic disorders which are associated with overweight will be excluded.

1
2
3 161
4
5 162
6
7
8 163
9
10 164
11
12 165
13
14 166
15
16 167
17
18
19 168
20
21 169
22
23 170
24
25 171
26
27
28 172
29
30 173
31
32 174
33
34 175
35
36 176
37
38
39 177
40
41 178
42
43 179
44
45 180
46
47 181
48
49
50 182
51
52 183
53
54 184
55
56 185
57
58 186
59
60 187

Types of intervention

Any type of mHealth intervention using apps. There is no restriction as to how the app delivers the intervention or intervention duration or the type of electronic platform (smartphones; tablets; etc.).

Types of outcomes

We will assess at baseline and then all outcomes at two further time points:

- End of intervention, as defined by trialist (primary time point of interest)
- Maximum follow up.

Primary outcomes

- BMI z-score
- Quality of life: as measured by any scale that has been validated for use in the target population (35).
- Proportion of participants with at least one serious adverse event (34).

Secondary outcomes

- Body weight measured in kg.
- Self-efficacy: as measured by a scale validated for use in children
- Anxiety
- Depression
- Proportion of participants with at least one adverse event not considered serious

Exploratory outcomes

- Body fat measured by bioimpedance or DEXA, there having been good correlation between total body fat % by bioimpedance DEXA ($r = 0.87$, $P < 0.001$) (36,37)

- Muscle mass (kg) via bioimpedance or DEXA (36,37)
- Individual serious and non-serious adverse events

Primary classification of mHealth apps

mHealth app interventions in overweight children cover a variety of typologies and related strategies. We have subsequently provided a systematic categorisation of these approaches for the systematic review. Whilst appreciating that there will be some overlap in the app characteristics, the categorisation aims to identify the primary purpose of the app in the intervention.

mHealth apps for overweight interventions usually target three different behavioural strategies - diet, physical activity and behavioural change (38). Apps are mainly targeted to monitor or motivate small improvements such as steps per day, duration and intensity of physical activity or counting calories for nutrition. Indeed, behaviour or lifestyle (which also includes nutrition and physical activity) integrates data and suggests activities to the users in order to motivate them and try to change their behaviour.

Based on these three strategies, the apps can be then divided into different categories according to the main characteristic which is listed below as main bullet points:

- Presence of devices
 - Standalone mobile applications without connected devices for data gathering
 - Mobile applications with devices (wearable devices, smart scales, etc.)
- Coach
 - Mobile applications with a real human coach who interacts with the users (phone calls or messages)
 - Mobile applications with a virtual coach which provides suggestions to the users by means of gathered data;
 - Mobile application without a coach: this app only gets data and shows them to the users;

- [Intervention (only if app includes a coach)]
 - Mobile application with a standard reminder/suggestion, like the standard calendar notification
 - Mobile application with an intelligent reminder/suggestion based on acquired data and habits
 - Mobile application without a direct intervention
- Reward
 - Mobile application with an intangible reward (virtual coins for in app purchase, emoji)
 - Mobile application with a tangible reward (money or discount coupons (39))
 - Mobile application without a reward.

Further app categories can be described based on the connection of the application and how users can download it.

- Cloud and social connectivity
- Mobile application connected with the cloud to store and process data;
- Standalone application without a connection.

Table 1 shows this app classification with some examples and scientific papers related to them (Additional File 1).

Search methods for identification of studies

Electronic searches

We will search the following databases:

- Cochrane Library
- MEDLINE
- Excerpta Medica database (Embase)
- PsycINFO
- IEEE Explore

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- Web of Science (SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC)
- CINAHL
- LILACS.

Searching other resources

- ClinicalTrials.gov (<http://www.clinicaltrials.gov/>)
- Google Scholar (<https://scholar.google.com/>)
- European Medicine Agency ([http:// www.ema.europa.eu/ema/](http://www.ema.europa.eu/ema/))
- United States Food and Drug Administration ([ww.fda.gov](http://www.fda.gov))
- Medicines and Healthcare Products Regulatory Agency ([https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory- agency](https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency))
- The World Health Organization (www.who.int/)
- Global Obesity Forum (previously International Association for the study of Obesity) (www.iaso.org)
- European Association for the study of Obesity (EASO) (easo.org)
- ICTRP Search Portal

Keywords used in the search strategy

- Obesity
- Overweight
- Smartphone apps
- Health apps
- m-health app
- Body mass index
- Weight gain

- Weight loss

- Hyperphagia

Preliminary search strategy for MEDLINE is enclosed as Additional File 2.

Data collection and analysis

Selection of studies

The review will follow the recommendations in the Cochrane Handbook for Systematic Reviews of Interventions and according to Keus et al and Jakobsen et al (40,41). The analyses will be performed using Review Manager (42) and Trial Sequential Analysis programme (43).

Two authors (RR and PP) will independently screen titles and abstracts. They will retrieve all relevant full text study/publication after which two authors will independently screen the full text in order to identify and record reasons for exclusion of the ineligible studies. We will resolve any disagreement through discussion.

GA, IL, JC and JJC are in charge of reviewing the manuscript and convalidate any situations of indecision on the inclusion criteria of paper.

Data extraction and management

Data extraction will be performed independently by at least two authors, who will both compare the extracted data. Disagreements will be resolved by a third author. We will assess duplicate publications and companion papers of a trial together to evaluate all available data simultaneously (maximise data extraction, correct bias assessment). Trial authors will be contacted by email to request any additional data which may not have been reported sufficiently or at all in the publication. Review Manager software will be used to extract data.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

293 **Assessment of risk of bias in included studies**

294 The risk of bias of every included trial will be evaluated independently by at least two authors In
295 case of any disagreement, discrepancies will be discussed with a third author and resolved by
296 consensus. The risk of bias will be assessed using the Cochrane’s ‘Risk of bias’ assessment tool
297 (44,45) and the Cochrane Effective Practice and Organisation of Care Group’s guidance (45). We
298 will evaluate the methodology in respect of:

- Random sequence generation
- Allocation concealment
- Blinding of participants and treatment providers
- Blinding of outcome assessment
- Incomplete outcome data
- Selective outcome reporting
- For profit bias
- Overall risk of bias

307 Classification of the trials will follow criteria defined in Additional File 3.

309 **Meta-analysis**

310 Both end-scores and change-from-baseline scores will be used to analyse continuous outcomes. If
311 both end-scores and change-from-baseline scores are reported then only end-scores will be used.
312 If only change-from-baseline scores are reported, these results together with end-scores will be
313 analysed in the same meta-analyses (44). Exploratory outcomes will be analysed using change from
314 baseline scores.

315 Data will be meta-analysed by RevMan 5 statistical software. We will use STATA statistical software
316 (STATA 2015) in case of zero event trials, where RevMan 5 zero event handling is insufficient
317 (46,47). We will report effect estimate using mean difference with 95% confidence intervals.

1.

Intervention effects will be assessed by both random-effects model meta-analyses and fixed-effect model meta-analyses (27,43,48), using the more conservative point estimate of the two. Three primary outcomes will be examined with $P \leq 0.025$ being statistically significant. An eight-step procedure will be used to assess if the thresholds for significance are crossed. Five secondary outcomes will be examined with $P \leq 0.017$ being statistically significant (37). The results of the exploratory outcomes will be considered hypothesis generating only.

Analysis of all included studies will be compared to a sensitivity analysis of studies at low risk of bias. If the results are similar, primary conclusions will be based at the time point closest to 12 months on the overall analysis. If the results differ, primary conclusions will be based on studies with a low risk of bias.

A table describing the types of serious adverse events in each trial will be provided.

Trial Sequential Analysis

Traditional meta-analysis runs the risk of random errors due to sparse data and repetitive testing of accumulating data when updating reviews. Trial Sequential Analysis will thus be used to analyse the outcomes in order to calculate the required information size and control the risks of type I errors and type II errors (26,27,47).

For continuous outcomes, Trial Sequential Analysis will use the observed SD, a mean difference of the observed SD/2, an alpha of 2.5% for the three primary outcomes, an alpha of 1.67% for the five secondary outcomes and a beta of 10%, with adjustment for observed diversity (49,50). Mean differences (MDs) and the standardised mean difference will be expressed with 95% confidence intervals (CI) for continuous outcomes, as well as the Trial Sequential Analysis adjusted CIs for MDs. We intend to use the proportion in the control group and the diversity estimated in the meta-analysis to provide reliable results.

1
2
3 343
4
5 344
6
7
8 345
9
10 346
11
12 347
13
14 348
15
16 349
17
18
19 350
20
21 351
22
23 352
24
25 353
26
27
28 354
29
30 355
31
32 356
33
34 357
35
36 358
37
38
39 359
40
41 360
42
43 361
44
45 362
46
47
48 363
49
50 364
51
52 365
53
54 366
55
56 367
57
58
59
60

For dichotomous outcomes, Trial Sequential Analysis will use the proportion of participants with an outcome in the control group, a relative risk reduction of 20%, an alpha of 2.5% for primary outcomes, an alpha of 1.67% for secondary outcomes, and a beta of 10%, with adjustment for observed diversity. We will calculate risk ratios with 95% CI for dichotomous outcomes, as well as Trial Sequential Analysis adjusted CIs.

Subgroup analyses

Subgroup analysis when analysing the primary outcomes will be performed as follows:

- Trials at high risk of bias trials compared to trials at low risk of bias trials.
- Trials stratified according to experimental interventions.
- Trials stratified according to weight status: overweight, obese or morbidly obese at the entry into the trial (6).
- Trial stratified according to the control interventions.
- Complexity: trials with participants with no co-morbidities compared to trials with participants pre-existing co-morbidities.
- Trials in which the experimental intervention was evaluated by either the parents or the child after the treatment sessions had been delivered compared to trials in which the experimental intervention was not evaluated by either the parents or the child after the treatment sessions had been delivered.

We will use the formal test for subgroup interactions in Review Manager (42).

Sensitivity analysis

To assess the potential impact of the missing data for dichotomous outcomes, we will perform the following sensitivity analyses:

1.

- 'Best-worst-case' scenario: we will assume that all participants lost to follow-up in the experimental group had no serious adverse events, including not developing any psychiatric disease such as an eating disorder.
- Worst-best case scenario: all dropouts/participants lost from the experimental group, but none from the control group experienced the outcome, including all randomised participants in the denominator.

Statistical heterogeneity will be assessed by visual inspection of the forest plots and I^2 statistic values (40). Underlying reasons behind statistical heterogeneity in meta-analyses will be investigated by assessing trial characteristics.

Summary of findings table

A summary of findings table using each of the prespecified primary and secondary outcomes will be reported using the GRADE considerations for studies which contribute data to the meta-analyses for the prespecified outcomes (34,40,51–64). Methods and recommendations described in Chapter 8 (Section 8.5) and Chapter 12 of the *Cochrane Handbook for Systematic Reviews of Interventions* (65) will be followed using GRADEpro software.

DISCUSSION

The objective of the review will be to compare the benefits and harms of different categories of mHealth apps for intervention of overweight in children. Currently, there are no systematic reviews which specifically compare the effects of mHealth apps to interventions in children with overweight. Previous systematic reviews in children have considered the efficacy of mobile health technologies more broadly in the role of weight management (56), but none have provided comprehensive coverage of the benefits and harms of mHealth apps. Hence, this evidence will hopefully help children and adolescents, their parents, and health professionals to make informed treatment decisions. This review will also highlight any gaps in the evidence base of such interventions which will help to shape the development and optimization of future potential interventions.

1
2
3 395
4
5 396
6
7
8 397
9
10 398
11
12 399
13
14 400
15
16 401
17
18
19 402
20
21 403
22
23 404
24
25 405
26
27 406
28
29
30 407
31
32 408
33
34 409
35
36 410
37
38
39 411
40
41 412
42
43 413
44
45 414
46
47 415
48
49
50 416
51
52 417
53
54 418
55
56 419
57
58 420
59 421
60
422

ETHICS AND DISSEMINATION

Acknowledgements We would like to thank Sarah Louise Klingenberg, Information Specialist at the Copenhagen Trial Unit, Centre for Clinical Intervention Research for her guidance and assistance on developing search methods keywords for search strategies.

Author contributions IL, RR, PP, GA, CG and JCJ wrote the first draft of the protocol. PP, RR, IL, GA, JCJ and CG have revised the protocol. All authors read and approved the manuscript. IL is the guarantor for the review.

Funding This research received no specific grant from any funding agency.

Availability of data and materials Not applicable.

Competing interests None known.

Patient consent Not required.

Patient and Public Involvement No patient involvement.

Provenance and peer review Not commissioned, externally peer reviewed.

REFERENCES

1. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. Int J Pediatr Obes. 2007/09/29. 2006;1(1):11–25.

2. Lobstein T. The prevention of obesity in children. Pediatr Endocrinol Rev. 2006/01/31.

2004;1 Suppl 3:471–5.

3. de Onis M, Blossner M, Borghi E. Global prevalence and trends of overweight and obesity among preschool children. *Am J Clin Nutr*. 2010/09/24. 2010;92(5):1257–64.
4. Organisation WH. COSI: Childhood Obesity Surveillance Initiative. Copenhagen: WHO; 2018.
5. Organisation WH. Obesity and Overweight [Internet]. Copenhagen; 2016. Available from: <http://www.who.int/mediacentre/factsheets/fs311/en/>
6. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. *BMJ*. 2000/05/08. 2000;320(7244):1240–3.
7. Short CE, DeSmet A, Woods C, Williams SL, Maher C, Middelweerd A, et al. Measuring Engagement in eHealth and mHealth Behavior Change Interventions: Viewpoint of Methodologies. *J Med Internet Res*. 2018 Nov;20(11):e292.
8. Colquitt JL, Loveman E, O'Malley C, Azevedo LB, Mead E, Al-Khudairy L, et al. Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in preschool children up to the age of 6 years. *Cochrane Database Syst Rev*. 2016/03/11. 2016;3:CD012105.
9. Al-Khudairy L, Loveman E, Colquitt JL, Mead E, Johnson RE, Fraser H, et al. Diet, physical activity and behavioural interventions for the treatment of overweight or obese adolescents aged 12 to 17 years. *Cochrane Database Syst Rev*. 2017;6:CD012691.
10. Mead E, Brown T, Rees K, Azevedo LB, Whittaker V, Jones D, et al. Diet, physical activity and behavioural interventions for the treatment of overweight or obese children from the age of 6 to 11 years. *Cochrane Database Syst Rev*. 2017/06/24. 2017;6:CD012651.
11. Tate EB, Spruijt-Metz D, O'Reilly G, Jordan-Marsh M, Gotsis M, Pentz MA, et al. mHealth approaches to child obesity prevention: successes, unique challenges, and next directions. *Transl Behav Med*. 2013/12/03. 2013;3(4):406–15.
12. Anderson J, Kamphorst B. Ethics of e-coaching: Implications of employing pervasive computing to promote healthy and sustainable lifestyles. 2014. 351–356 p.
13. Baroni I, Nalin M, Coti Zelati M, Oleari E, Sanna A. Designing motivational robot: How robots might motivate children to eat fruits and vegetables. Vol. 2014. 2014.
14. Andreoni G, Perego P, Frumento E, editors. *m_Health Current and Future Applications* [Internet]. Cham: Springer International Publishing; 2019. (EAI/Springer Innovations in Communication and Computing). Available from: <http://link.springer.com/10.1007/978-3-030-02182-5>
15. Bardus M, Smith JR, Samaha L, Abraham C. Mobile Phone and Web 2.0 Technologies for Weight Management: A Systematic Scoping Review. *J Med Internet Res*. 2015 Nov;17(11):e259.
16. Flores Mateo G, Granado-Font E, Ferré-Grau C, Montaña-Carreras X. Mobile Phone Apps to Promote Weight Loss and Increase Physical Activity: A Systematic Review and Meta-Analysis. *J Med Internet Res* [Internet]. 2015 Nov 10;17(11):e253. Available from: <http://www.jmir.org/2015/11/e253/>
17. Badawy SM, Kuhns LM. Texting and Mobile Phone App Interventions for Improving

1

2

3 465

4 466

5 467

6 467

7 468

8 469

9 470

10 470

11 471

12 472

13 473

14 474

15 474

16 475

17 476

18 477

19 478

20 478

21 479

22 480

23 481

24 482

25 482

26 483

27 484

28 485

29 485

30 486

31 487

32 488

33 488

34 489

35 490

36 490

37 491

38 492

39 493

40 494

41 495

42 496

43 497

44 498

45 499

46 499

47 500

48 501

49 502

50 502

51 503

52 504

53 505

54 505

55 506

56 507

57 507

58 507

59 507

60 507

Adherence to Preventive Behavior in Adolescents: A Systematic Review. JMIR mHealth uHealth [Internet]. 2017 Apr 19;5(4):e50. Available from: <http://mhealth.jmir.org/2017/4/e50/>

18. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. *Ann Intern Med*. 2001/12/04. 2001;135(11):982–9.
19. Schunemann HJ, Wiercioch W, Brozek J, Etzeandía-Ikobaltzeta I, Mustafa RA, Manja V, et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. *J Clin Epidemiol*. 2016/10/08. 2017;81:101–10.
20. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised, controlled trials. *Ann Intern Med* [Internet]. 2012;157. Available from: <https://doi.org/10.7326/0003-4819-157-6-201209180-00537>
21. Savovic J, Jones H, Altman D, Harris R, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. *Heal Technol Assess*. 2012/09/20. 2012;16(35):1–82.
22. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *Jama*. 1995/02/01. 1995;273(5):408–12.
23. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. *BMJ*. 2008/03/05. 2008;336(7644):601–5.
24. Lundh A, Sismondo S, Lexchin J, Busuioac OA, Bero L. Industry sponsorship and research outcome. *Cochrane Database Syst Rev*. 2012/12/14. 2012;12:Mr000033.
25. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? *Lancet*. 1998/09/24. 1998;352(9128):609–13.
26. Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta-analysis. *BMC Med Res Methodol* [Internet]. 2017;17(1):39. Available from: <https://doi.org/10.1186/s12874-017-0315-7>
27. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. *BMC Med Res Methodol*. 2010/01/01. 2009;9:86.
28. Boulos MN, Brewer AC, Karimkhani C, Buller DB, Dellavalle RP. Mobile medical and health apps: state of the art, concerns, regulatory control and certification. *Online J Public Heal Inf*. 2014/04/01. 2014;5(3):229.
29. Gabrielli S, Dianti M, Maimone R, Betta M, Filippi L, Ghezzi M, et al. Design of a Mobile App for Nutrition Education (TreC-LifeStyle) and Formative Evaluation With Families of Overweight Children. *JMIR Mhealth Uhealth*. 2017/04/15. 2017;5(4):e48.
30. Kim K, Christine H, Young E, Sabee C. Youth-centered design and usage results of the iN Touch mobile self-management program for overweight/obesity. Vol. 19. 2015.

31. Ronimus M, Kujala J, Tolvanen A, Lyytinen H. Children's engagement during digital game-based learning of reading: The effects of time, rewards, and challenge. *Comput Educ.* 2014 Feb;71:237–46.
32. Watters C, Author M, Abouzied A, Cox A, Kellar M, Kharrazi H, et al. Extending the Use of Games in Health Care. Vol. 5. 2006.
33. Breton ER, Fuemmeler BF, Abrams LC. Weight loss-there is an app for that! But does it adhere to evidence-informed practices? *Transl Behav Med.* 2011/12/01. 2011;1(4):523–9.
34. Garattini S, Jakobsen JC, Wetterslev J, Bertele V, Banzi R, Rath A, et al. Evidence-based clinical practice: Overview of threats to the validity of evidence and how to minimise them. *Eur J Intern Med.* 2016/05/11. 2016;32:13–21.
35. Ahuja B, Klassen AF, Satz R, Malhotra N, Tsangaris E, Ventresca M, et al. A review of patient-reported outcomes for children and adolescents with obesity. *Qual Life Res.* 2013/06/27. 2014;23(3):759–70.
36. A. B. Social foundations of thought and action: A social cognitive theory. Englewood Cliffs: Prentice-Hall; 1986.
37. Murtagh J, Dixey R, Rudolf M. A qualitative investigation into the levers and barriers to weight loss in children: opinions of obese children. *Arch Dis Child.* 2006/07/06. 2006;91(11):920–3.
38. Puigdomenech E, Martin A, Lang A, Adorni F, Gomez SF, McKinstry B, et al. Promoting healthy teenage behaviour across three European countries through the use of a novel smartphone technology platform, PEGASO fit for future: study protocol of a quasi-experimental, controlled, multi-Centre trial. *BMC Med Inform Decis Mak [Internet].* 2019 Dec 17;19(1):278. Available from: <https://bmcmmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-019-0958-x>
39. Pedersen, Carmen and AH. Smart Technology for Health and Well-being. *J Fam Consum Sci.* 2018;110(2):55–6.
40. Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. *BMC Med Res Methodol.* 2014/11/25. 2014;14:120.
41. Keus F, Wetterslev J, Gluud C, Laarhoven CJ. Evidence at a glance: error matrix approach for over-viewing available evidence. *BMC Med Res Methodol [Internet].* 2010;10. Available from: <https://doi.org/10.1186/1471-2288-10-90>
42. Collaboration C. Review Manager. Copenhagen: Nordic Cochrane Centre; 2014.
43. Thorlund K, Wetterslev J, Brok J, Imberger G et al EJ. User manual for trial sequential analysis (TSA). [Internet]. 2011. Available from: www.ctu.dk/tsa
44. Davey J, Turner RM, Clarke MJ, Higgins JP. Characteristics of meta-analyses and their component studies in the Cochrane Database of Systematic Reviews: a cross-sectional, descriptive analysis. *BMC Med Res Methodol.* 2011/11/26. 2011;11:160.
45. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ.* 2011/02/12. 2011;342:d549.
46. Demets DL. Methods for combining randomized clinical trials: strengths and limitations. *Stat Med.* 1987/04/01. 1987;6(3):341–50.

- 1
- 2
- 3 550 47. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm
4 551 evidence is reached in cumulative meta-analysis. *J Clin Epidemiol* [Internet]. 2008;61.
5 552 Available from: <https://doi.org/10.1016/j.jclinepi.2007.03.013>
- 7 553 48. Keus F, Wetterslev J, Gluud C, Gooszen HG, van Laarhoven CJ. Trial sequential analyses of
8 554 meta-analyses of complications in laparoscopic vs. small-incision cholecystectomy: more
9 555 randomized patients are needed. *J Clin Epidemiol*. 2009/12/17. 2010;63(3):246–56.
- 11 556 49. Proposal for a good clinical practice directive. *Bull Med Ethics*. 2001/10/20. 1998;No. 135:6–
12 557 11.
- 14 558 50. StataCorp. StataCorp Statistical Software [Internet]. Release 14. College Station: StataCorp
15 559 LP; 2014. Available from: <http://www.stata.com>
- 17 560 51. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines:
18 561 7. Rating the quality of evidence--inconsistency. *J Clin Epidemiol*. 2011/08/02.
19 562 2011;64(12):1294–302.
- 21 563 52. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines:
22 564 8. Rating the quality of evidence--indirectness. *J Clin Epidemiol*. 2011/08/02.
23 565 2011;64(12):1303–10.
- 25 566 53. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE
26 567 guidelines: 9. Rating up the quality of evidence. *J Clin Epidemiol*. 2011/08/02.
27 568 2011;64(12):1311–6.
- 29 569 54. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE
30 570 guidelines: 11. Making an overall rating of confidence in effect estimates for a single
31 571 outcome and for all outcomes. *J Clin Epidemiol*. 2012/05/01. 2013;66(2):151–7.
- 33 572 55. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12.
34 573 Preparing summary of findings tables-binary outcomes. *J Clin Epidemiol*. 2012/05/23.
35 574 2013;66(2):158–72.
- 37 575 56. Darling KE, Sato AF. Systematic Review and Meta-Analysis Examining the Effectiveness of
38 576 Mobile Health Technologies in Using Self-Monitoring for Pediatric Weight Management. *Child*
39 577 *Obes*. 2017/05/05. 2017;13(5):347–55.
- 41 578 57. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an
42 579 emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*.
43 580 2008/04/26. 2008;336(7650):924–6.
- 45 581 58. Schunemann HJ, Best D, Vist G, Oxman AD. Letters, numbers, symbols and words: how to
46 582 communicate grades of evidence and recommendations. *Cmaj*. 2003/10/01.
47 583 2003;169(7):677–80.
- 49 584 59. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new
50 585 series of articles in the *Journal of Clinical Epidemiology*. *J Clin Epidemiol*. 2010/12/28.
51 586 2011;64(4):380–2.
- 53 587 60. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of
52 588 evidence and strength of recommendations. *BMJ*. 2004/06/19. 2004;328(7454):1490.
- 54 589 61. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1.
55 590 Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol*.
56 591 2011/01/05. 2011;64(4):383–94.

62. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol*. 2011/01/05. 2011;64(4):395–400.
63. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). *J Clin Epidemiol*. 2011/01/21. 2011;64(4):407–15.
64. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. *J Clin Epidemiol*. 2011/08/02. 2011;64(12):1277–82.
65. Chandler J, Cumpston M, Li T, Page MJ, Welch VA. *Cochrane handbook for systematic reviews of interventions*. John Wiley & Sons; 2019.

Appendices


Additional File 1: Table 1 Classification of mHhealth apps.

Additional File 2: Preliminary search strategy for MEDLINE (Ovid).

Additional File 3: Classification of randomised trials at low and high risk of bias.

Images legends

Figure 1: Overweight and obesity prevalence values based on WHO definition - COSI 2015-2017 (4)



Overweight and obesity prevalence values based on WHO definition - COSI 2015-2017 (4)

Table 1 Classification of mhealth apps

Category	Name of the app	Authors	Year	Paper Title
App with device	Collective Intelligence	Addo et al	2013	Toward collective intelligence for fighting obesity
Standalone	iN Touch	Kim et al	2015	Youth-centered Design and Usage Results of the iN Touch Mobile Self-management Program for Overweight/Obesity
Real (Human)	Personal Wellness Coach	Asselin et al	2005	Implementation and evaluation of the personal wellness coach
Virtual	Move it move it	Frost et al	2012	We Like to Move It Move It!: Motivation and Parasocial Interaction
None	iN Touch	Kim et al	2015	Youth-centered Design and Usage Results of the iN Touch Mobile Self-management Program for Overweight/Obesity
Reminder	Txt2Bfit	Partridge et al	2015	Effectiveness of a mHealth Lifestyle Program With Telephone Support (TXT2BFIT) to Prevent Unhealthy Weight Gain in Young Adults: Randomized Controlled
Smart Suggestion	Teenagers and Digital Coaching	Kettunen et al	2018	Can Sport and Wellness Technology be My Personal Trainer?—Teenagers and Digital Coaching
None	MyFitnessPal	Levinson et al	2017	My Fitness Pal calorie tracker usage in the eating disorders
Intangible				**PEGASO DSAHBOARD (not published)
Tangible	Pegaso City	Caon et al	2016	PEGASO Companion: A Mobile App to Promote Healthy Lifestyles Among Adolescents
None	Fitbit for Obese	Yoost et al	2018	The Use of Fitbit Technology Among Rural Obese Adolescents
Connected	Collective Intelligence	Addo et al	2013	Toward collective intelligence for fighting obesity
Standalone	Personal Wellness Coach	Asselin et al	2005	Implementation and evaluation of the personal wellness coach

Search strategies for
Apps vs no apps
Preliminary searches performed 23 April 2019

Total number of records identified: 4494 records
Number of duplicates excluded: 743 records
Number of records in final list: 3751 records

Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (2019, Issue 4) (546 hits)

- #1 MeSH descriptor: [Obesity] explode all trees
- #2 MeSH descriptor: [Hyperphagia] explode all trees
- #3 MeSH descriptor: [Body Mass Index] explode all trees
- #4 MeSH descriptor: [Weight Gain] explode all trees
- #5 MeSH descriptor: [Weight Loss] explode all trees
- #6 MeSH descriptor: [Anti-Obesity Agents] 1 tree(s) exploded
- #7 (Pickwick* syndrom* or Prader willi syndrom* or obes* or adipos* or overweight* or 'over weight*' or overeat* or 'over eat*' or 'over feed*' or overfeed* or binge eating disorder* or 'fat overload' syndrom* or (weight and (gain or cycling or reduc* or loss or losing or maint* or decreas* or watch* or diet* or control*)))ti,ab
- #8 #1 or #2 or #3 or #4 or #5 or #6 or #7
- #9 MeSH descriptor: [Mobile Applications] explode all trees
- #10 ((mobile or smartphone or telephone or virtual or digital or wellness or medical or dietary or physical activity or intervention or treatment or weight or calorie) and (app or coach or tracker))
- #11 (m*health or mobile health or p*health or personal health or 'in touch' or txt2bfit or pegaso or fitbit or collective intelligence or 'move it' or myfitnesspal)
- #12 #9 or #10 or #11
- #13 #8 and #12

MEDLINE Ovid (1946 to April 2019) (510 hits)

- 1. exp Obesity/
- 2. exp Hyperphagia/
- 3. exp body mass index/
- 4. exp Weight Gain/
- 5. exp Weight Loss/
- 6. exp Anti-Obesity Agents/
- 7. (Pickwick* syndrom* or Prader willi syndrom* or obes* or adipos* or overweight* or 'over weight*' or overeat* or 'over eat*' or 'over feed*' or overfeed* or binge eating disorder* or 'fat overload' syndrom* or (weight and (gain or cycling or reduc* or loss or losing or maint* or decreas* or watch* or diet* or control*)))ti,ab.
- 8. 1 or 2 or 3 or 4 or 5 or 6 or 7
- 9. exp Mobile Applications/
- 10. ((mobile or smartphone or telephone or virtual or digital or wellness or medical or dietary or physical activity or intervention or treatment or weight or calorie) and (app or coach or tracker)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
- 11. (m*health or mobile health or p*health or personal health or 'in touch' or txt2bfit or pegaso or fitbit or collective intelligence or 'move it' or myfitnesspal).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
- 12. 9 or 10 or 11
- 13. 8 and 12
- 14. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
- 15. 13 and 14

Embase Ovid (1974 to April 2019) (802 hits)

- 1. exp obesity/
- 2. exp hyperphagia/

3. exp body mass/
4. exp body weight gain/
5. exp body weight loss/
6. exp antiobesity agent/
7. (Pickwick* syndrom* or Prader willi syndrom* or obes* or adipos* or overweight* or 'over weight*' or overeat* or 'over eat*' or 'over feed*' or overfeed* or binge eating disorder* or 'fat overload' syndrom* or (weight and (gain or cycling or reduc* or loss or losing or maint* or decreas* or watch* or diet* or control*))) .ti,ab.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp mobile application/
10. ((mobile or smartphone or telephone or virtual or digital or wellness or medical or dietary or physical activity or intervention or treatment or weight or calorie) and (app or coach or tracker)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
11. (m*health or mobile health or p*health or personal health or 'in touch' or txt2bfit or pegaso or fitbit or collective intelligence or 'move it' or myfitnesspal).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
12. 9 or 10 or 11
13. 8 and 12
14. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
15. 13 and 14

LILACS (Bireme; 1982 to April 2019) (24 hits)

(Pickwick\$ syndrom\$ or Prader willi syndrom\$ or obes\$ or adipos\$ or overweight\$ or 'over weight\$' or overeat\$ or 'over eat\$' or 'over feed\$' or overfeed\$ or binge eating disorder\$ or 'fat overload' syndrom\$ or (weight and (gain or cycling or reduc\$ or loss or losing or maint\$ or decreas\$ or watch\$ or diet\$ or control\$))) [Words] and (((mobile or smartphone or telephone or virtual or digital or wellness or medical or dietary or physical activity or intervention or treatment or weight or calorie) and (app or coach or tracker)) or (m\$health or mobile health or p\$health or personal health or 'in touch' or txt2bfit or pegaso or fitbit or collective intelligence or 'move it' or myfitnesspal)) [Words]

Science Citation Index Expanded (SCI-EXPANDED) (1900 to April 2019), Social Sciences Citation Index (SSCI) (1956 to April 2019), Arts & Humanities Citation Index (A&HCI) (1975 to April 2019), Conference Proceedings Citation Index- Science (CPCI-S) (1990- April 2019), Conference Proceedings Citation Index- Social Science & Humanities (CPCI-SSH) (1990- April 2019), Emerging Sources Citation Index (ESCI) (2015 to April 2019), Web of Science Core Collection: Chemical Indexes Current Chemical Reactions (CCR-EXPANDED) (1986 to April 2019), Index Chemicus (IC) (1993 to April 2019) (Web of Science) (2612 hits)

#7 #6 AND #5

#6 TS=(random* or blind* or placebo* or meta-analys*)

#5 #4 AND #1

#4 #3 OR #2

#3 TS=(m*health or mobile health or p*health or personal health or 'in touch' or txt2bfit or pegaso or fitbit or collective intelligence or 'move it' or myfitnesspal)

#2 TS=((mobile or smartphone or telephone or virtual or digital or wellness or medical or dietary or physical activity or intervention or treatment or weight or calorie) and (app or coach or tracker))

#1 TS=(Pickwick* syndrom* or Prader willi syndrom* or obes* or adipos* or overweight* or 'over weight*' or overeat* or 'over eat*' or 'over feed*' or overfeed* or binge eating disorder* or 'fat overload' syndrom* or (weight and (gain or cycling or reduc* or loss or losing or maint* or decreas* or watch* or diet* or control*)))

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Assessment of risk of bias in included studies

Random sequence generation

Low risk: If sequence generation was achieved using computer random number generator or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were also considered adequate if performed by an independent adjudicator.

Unclear risk: If the method of randomisation was not specified, but the trial was still presented as being randomised.

High risk: If the allocation sequence is not randomised or only quasi-randomised. These trials will be excluded.

Allocation concealment

Low risk: If the allocation of patients was performed by a central independent unit, on-site locked computer or identical-looking numbered sealed envelopes.

Uncertain risk: If the trial was classified as randomised but the allocation concealment process was not described.

High risk: If the allocation sequence was familiar to the investigators who assigned participants.

Blinding of participants and treatment providers

Low risk: If the participants and the treatment providers were blinded to intervention allocation and this was described.

Uncertain risk: If the procedure of blinding was insufficiently described.

High risk: If blinding of participants and the treatment providers was not performed.

Blinding of outcome assessment

Low risk of bias: If it was mentioned that outcome assessors were blinded and this was described.

Uncertain risk of bias: If it was not mentioned if the outcome assessors in the trial were blinded or the extent of blinding was insufficiently described.

High risk of bias: If no blinding or incomplete blinding of outcome assessors was performed.

Incomplete outcome data

Low risk of bias: If missing data were unlikely to make treatment effects depart from plausible values. This could be either (1) there were no drop-outs or withdrawals for all outcomes, or (2) the numbers and reasons for the withdrawals and drop-outs for all outcomes were clearly stated and could be described as being similar to both groups. Generally, the trial is judged as at a low risk of bias due to incomplete outcome data if drop-outs are less than 5%. However, the 5% cut-off is not definitive.

Uncertain risk of bias: If there was insufficient information to assess whether missing data were likely to induce bias on the results.

High risk of bias: If the results were likely to be biased due to missing data either because the pattern of drop-outs could be described as being different in the two intervention groups or the trial used improper methods in dealing with the missing data (e.g. last observation carried forward).

Selective outcome reporting

Low risk of bias: If a protocol was published before or at the time the trial was begun and the outcomes specified in the protocol were reported on. If there is no protocol

or the protocol was published after the trial has begun, reporting of serious adverse events will grant the trial a grade of low risk of bias.

Uncertain risk of bias: If no protocol was published and the outcome of serious adverse events were not reported on.

High risk of bias: If the outcomes in the protocol were not reported on.

Other risks of bias

Low risk of bias: If the trial appears to be free of other components (for example, academic bias or for-profit bias) that could put it at risk of bias.

Unclear risk of bias: If the trial may or may not be free of other components that could put it at risk of bias.

High risk of bias: If there are other factors in the trial that could put it at risk of bias (for example, authors conducted trials on the same topic, for-profit bias, etc.).

Overall risk of bias

Low risk of bias: The trial will be classified as overall 'low risk of bias' only if all of the bias domains described in the above paragraphs are classified as 'low risk of bias'.

High risk of bias: The trial will be classified as 'high risk of bias' if any of the bias risk domains described in the above are classified as 'unclear' or 'high risk of bias'.

We will assess the domains 'blinding of outcome assessment', 'incomplete outcome data', and 'selective outcome reporting' for each outcome result. Thus, we can assess the bias risk for each outcome assessed in addition to each trial. Our primary conclusions will be based on the results of our primary outcome results with overall low risk of bias. Both our primary and secondary conclusions will be presented in the summary of findings tables.

Reporting checklist for protocol of a systematic review.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preorting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

		Reporting Item	Page Number
Title			
Identification	#1a	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	n/a
Registration			
	#2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors			
Contact	#3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1

1	Contribution	#3b	Describe contributions of protocol authors and identify the guarantor of the review	16
2				
3				
4				
5	Amendments			
6				
7		#4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	n/a
8				
9				
10				
11				
12				
13				
14	Support			
15				
16				
17	Sources	#5a	Indicate sources of financial or other support for the review	16
18				
19	Sponsor	#5b	Provide name for the review funder and / or sponsor	n/a
20				
21	Role of sponsor or funder	#5c	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	n/a
22				
23				
24				
25	Introduction			
26				
27				
28	Rationale	#6	Describe the rationale for the review in the context of what is already known	2
29				
30				
31				
32	Objectives	#7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	6
33				
34				
35				
36				
37	Methods			
38				
39				
40	Eligibility criteria	#8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6
41				
42				
43				
44				
45				
46				
47	Information sources	#9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	9
48				
49				
50				
51				
52	Search strategy	#10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	10
53				
54				
55				
56				
57				
58	Study records -	#11a	Describe the mechanism(s) that will be used to manage	11
59				
60				

data management		records and data throughout the review	
Study records - selection process	#11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	11
Study records - data collection process	#11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	11
Data items	#12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	7
Outcomes and prioritization	#13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	7
Risk of bias in individual studies	#14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	11
Data synthesis	#15a	Describe criteria under which study data will be quantitatively synthesised	14
Data synthesis	#15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I ² , Kendall's τ)	14
Data synthesis	#15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	11
Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the type of summary planned	n/a
Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	12

1

Confidence in

#17

Describe how the strength of the body of evidence will be

14

2

3

cumulative

assessed (such as GRADE)

4

evidence

5

6

7

The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License

8

CC-BY 4.0. This checklist was completed on 24. June 2019 using <https://www.goodreports.org/>, a

9

10

tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

BMJ Open

Mobile health applications for intervention in children and adolescent with overweight. A protocol for systematic review with meta analysis and Trial Sequential Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032570.R2
Article Type:	Protocol
Date Submitted by the Author:	07-Jul-2020
Complete List of Authors:	Perego, Paolo; Politecnico di Milano, Design Department Rashid, Rajeeb; The University of Edinburgh Department of Child Life and Health, Department of Child Health Gluud, Christian; Copenhagen Trial Unit (CTU), Center for Clinical Intervention Research Jakobsen, Janus; The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital; Holbaek Sygehus, Department of Cardiology Andreoni, Giuseppe; Politecnico di Milano, Design Dept. Lissau, Inge; University Hospital Copenhagen, Clinical Research Centre
Primary Subject Heading:	Paediatrics
Secondary Subject Heading:	Global health, Paediatrics, Public health
Keywords:	Paediatric endocrinology < DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH, Information technology < BIOTECHNOLOGY & BIOINFORMATICS, PAEDIATRICS, PREVENTIVE MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Comparison of different Mobile health applications for intervention in children and adolescent with overweight. A protocol for systematic review with meta analysis and Trial Sequential Analysis

Perego P¹, Rashid R², Gluud C³, Jakobsen JC^{3,4,5}, Andreoni G¹, Lissau I^{6,7}

Affiliations

¹Department of Design, Politecnico di Milano, Milan, Italy

²Department of Child Health, University of Edinburgh, Edinburgh, Scotland

³Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

⁴Department of Cardiology, Holbæk Hospital, Denmark

⁵Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark

⁶ Clinical Research Centre, University Hospital Copenhagen, 2650 Hvidovre, Denmark

⁷Department of Clinical Sciences, Faculty of Medicine, University of Lund, Lund, Sweden.

Correspondence to

Dr. Inge Lissau, PhD

Postal Address: Clinical Research Centre, University Hospital Copenhagen, Hvidovre Kettegaard Alle 30, DK-2650, Hvidovre, Denmark

Telephone number: 0045-53881018

E-mail: info@ingelissau.dk

Word count 3401

1
2
3 28
4
5 29
6
7 30
8
9 31
10
11
12 32
13
14 33
15
16 34
17
18 35
19
20 36
21
22
23 37
24
25 38
26
27 39
28
29 40
30
31 41
32
33 42
34
35 43
36
37 44
38
39 45
40
41 46
42
43 47
44
45 48
46
47 49
48
49 50
50
51 51
52
53 52
54
55 53
56
57
58
59
60 54

ABSTRACT

Introduction Overweight in children is increasing worldwide. Innovative smartphone health applications (mHealth apps) have either sought to deliver single or multi-component interventions for the management of overweight in children. However, the clinical effects of these apps are poorly explored. The objective of the review will be to compare the benefits and harms of different categories of mHealth apps for intervention of overweight in children. **Methods and analysis** We will include randomised clinical trials irrespective of publication type, year, status, or language. Children and adolescents between 0-18 years will be referred to as children in the remaining part of the paper. Children with all degrees of overweight included obesity and morbidly obese in the remaining part of the paper will be referred to as overweight. We plan to classify different apps according to type of intervention, measurement device, coaching and reward system. The following databases will be used: Cochrane Library, Excerpta Medica database (Embase), PsycINFO, PubMed, IEEE Explore and Web of Science, CINAHL and LILACS. Primary outcomes will be body mass index z-score (BMI z-score), quality of life, and serious adverse event. Secondary outcomes will be body weight, self-efficacy, anxiety, depression, and adverse event not considered serious. Study inclusion, data extraction, and bias risk assessment will be conducted independently by at least two authors. We will assess risk of bias through eight domains and control risks of random errors with Trial Sequential Analysis. The quality of the evidence will be assessed using Grading of Recommendations Assessment, Development and Evaluation Tool (GRADE).

Ethics and dissemination As the protocol is for a systematic reviews, we have not included any patient data and we do not require ethical approval. This review will be published in a peer-reviewed journal.

PROSPERO registration number CRD42019120266

Keywords Obesity, overweight, children, adolescents, smartphone apps, health apps, mHealth app, management, intervention, treatment

ARTICLE SUMMARY

Strengths and Limitations of this study

- This review aims to be the first systematic review to investigate the benefits and harms of mobile health app interventions in children with overweight following Cochrane guidelines.
- A comprehensive search strategy will be used with a large number of databases searched, and only Randomised Controlled Trials in children with overweight will be included.
- The review will perform meta-analysis, Trial Sequential Analysis and use the Grading of Recommendations Assessment, Development and Evaluation Tool.
- We expect high heterogeneity across studies which may lead to challenges in performing a Meta-analysis.
- It is anticipated that many papers will not provide sufficient details on all variables of interest and will lead to reliance on communication with corresponding authors for additional information.

INTRODUCTION

The prevalence of overweight are increasing worldwide among children irrespective of socio-economic status (1–3). By 2025 more than 260 million children aged 5-17 years may be overweight, including 91 million obese according to data from Global Burden of Disease collaborative for 2000 and 2013 (4,5). The International Task Force of Obesity produced age and gender specific cut-off for the definition of overweight and obesity in children (6). Throughout this paper we will use the term overweight for all children with overweight including all levels of obesity.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

83 These trends of increasing overweight will have long-term consequences on cardiovascular disease,
84 insulin resistance, type 2 diabetes, and cancer (endometrial, breast and colon), resulting in a
85 significant burden on health services across the world (4). Recently, there has been an exponential
86 growth in connected devices such as smartphones and tablets, supporting the development of new
87 services. A plethora of software applications (apps) running on these devices are appearing on the
88 market (Figure 1). Health apps thus represent a huge area which potentially exploits the new
89 paradigm of mHealth – Mobile Health. This refers to medicine and public health services supported
90 by mobile devices. mHealth apps are commonly used in disease surveillance, treatment support and
91 for educating children about prevention. However, despite the potential opportunities of mHealth,
92 the main issue of these applications is the ability to engage the users to keep them motivated using
93 the app, an aspect that is even more difficult if the users are young (7).

94
95 Children are “millennials” and “natively digital” hence mobile technologies are potentially relevant
96 and accessible tools for them, even in their health management. In this paper, we combined these
97 two elements to analyse the mutual inter-relationships between the use of mobile systems to
98 counteract overweight in children. Recent Cochrane reviews highlighted the benefits of multi-
99 component interventions over single approach programmes on treating children with overweight.
100 The authors, however, noted the paucity of good quality trials on multi-component interventions (8–
101 10).

102
103 **mHealth apps**

104 Smartphones increase the possibility to interact with people in a more personalised and tailored
105 manner. They enable the building of platforms for adaptive interventions with visually appealing and
106 engaging multimedia modalities which can be adjusted by the user based on their preferences (11).
107 mHealth apps have the ability to support children to achieve and maintain a healthy and sustainable
108 lifestyle by supporting and strengthening their self-regulatory capacities (12,13). They offer potential
109 advantages over traditional face-to-face methods for delivering health-related interventions (14–

17). These include cost-effective dissemination, real-time data collection and feedback, lowered participant burden, and flexible program tailoring (11).

No reviews to date, to our best knowledge, have specifically compared the efficacy of different categories of apps for interventions in children with overweight. In addition, whilst previous reviews have commented upon the significant risk of bias in many studies, there has not been a consistency in including control of bias, the play of chance and assessing the quality with GRADE assessment in these reviews (18–27).

Nutrition and diet apps represent a popular area of mHealth, offering the possibility of delivering behavioural change interventions for healthy eating and weight management in a scalable and cost-effective way. Use of commercial apps for paediatric weight management often fail to retain users because of a lack of theoretical background and evidence-based content. However, mHealth apps that are more evidence-based are often found less engaging and popular among consumers (28). Approaching the apps development process from a multidisciplinary, expert and user-centred design perspective is more likely to help overcome these limitations. They may also provide easier adoption and integration of nutritional education apps within primary and secondary care interventions (29,30).

Such a process has been transitioned into health game apps where long-term use is dependent on providing easy and continual gaming access on both smartphones and tablets; offer games that can be personalised and are adaptable based on the child's interests; and maintain novelty and interest in the treatment over time (31). This framework not only provides a benefit to the children involved, but also provides user data to the coaches, clinicians, and health researchers involved in the child's treatment regime (32). In addition, whilst many apps tended to focus either on nutrition or on

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

physical activity, very few apps managed to adhere to or deliver a comprehensive overweight intervention for children due to a failure to support a spectrum of important target behaviours (33).

The role of health researchers is therefore to evaluate the evidence base, efficacy, and quality of different apps to ascertain whether these apps may have a part to play in the management of childhood overweight. In addition, assessment of the effect of the interventions have not been evaluated taking risks of bias, risks of random errors, type of control interventions, as well as the quality of evidence into account (34).

Objective

The objective of the review will be to compare the benefits and harms of different categories of mHealth apps in interventions for overweight in children.

METHODS AND ANALYSIS

This work consists in a protocol for systematic review with meta analysis and trial sequential analysis with the aim to compare different typology of mobile health applications for intervention in children and adolescent with overweight. The paper is continuation of the previous work (35) by the same authors in which the effectiveness of the use of applications in the prevention of obesity was studied. The methods section overlaps in part with our previous publication and with other Cochrane protocols and reviews, especially those following Cochrane methodology and using trial sequential analysis which have common authors (C. Gluud and J.C. Jakobsen).

Criteria for considering studies for this review

Types of studies

Randomised clinical trials irrespective of language, publication status, publication type, or publication year up to July 2020 will be included in the review. Eligible studies which are not published in English

will be translated using Google translate. Authors will be contacted to check if an English translation is available or to clarify any queries.

Types of participants

All children who are overweight (including all levels of obesity) up to 18 years of age (as defined earlier). Children with associated co-morbidities, either physical or psychological secondary to overweight and obesity will be included. Children with causes of overweight due to medication such as steroids, or genetic disorders which are associated with overweight will be excluded.

Types of intervention

Any type of mHealth intervention using apps. There is no restriction as to how the app delivers the intervention or intervention duration or the type of electronic platform (smartphones; tablets; etc.).

Types of outcomes

We will assess at baseline and then all outcomes at two further time points:

- End of intervention, as defined by trialist (primary time point of interest)
- Maximum follow up.

Primary outcomes

- BMI z-score
- Quality of life: as measured by any scale that has been validated for use in the target population (36).
- Proportion of participants with at least one serious adverse event (34).

Secondary outcomes

- Body weight measured in kg.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- Self-efficacy: as measured by a scale validated for use in children
- Anxiety
- Depression
- Proportion of participants with at least one adverse event not considered serious

Exploratory outcomes

- Body fat measured by bioimpedance or DEXA, there having been good correlation between total body fat % by bioimpedance DEXA ($r = 0.87$, $P < 0.001$) (37,38)
- Muscle mass (kg) via bioimpedance or DEXA (37,38)
- Individual serious and non-serious adverse events

Primary classification of mHealth apps

mHealth app interventions in overweight children cover a variety of typologies and related strategies. We have subsequently provided a systematic categorisation of these approaches for the systematic review. Whilst appreciating that there will be some overlap in the app characteristics, the categorisation aims to identify the primary purpose or key component of the app in the intervention.

mHealth apps for overweight interventions usually target three different strategies – dietary change, increase in physical activity and behavioural change (39). Apps are mainly targeted to monitor or motivate small improvements such as steps per day, duration and intensity of physical activity or counting calories for nutrition. Indeed, behaviour or lifestyle (which also includes nutrition and physical activity) integrates data and suggests activities to the users in order to motivate them and try to change their behaviour.

Based on these three strategies, the apps can be then divided into different categories according to the main characteristic which is listed below as main bullet points:

- Presence of devices

- Standalone mobile applications without connected devices for data gathering
- Mobile applications with devices (wearable devices, smart scales, etc.)
- Coach
 - Mobile applications with a real human coach who interacts with the users (phone calls or messages)
 - Mobile applications with a virtual coach which provides suggestions to the users by means of gathered data;
 - Mobile application without a coach: this app only gets data and shows them to the users;
- [Intervention (only if app includes a coach)]
 - Mobile application with a standard reminder/suggestion, like the standard calendar notification
 - Mobile application with an intelligent reminder/suggestion based on acquired data and habits
 - Mobile application without a direct intervention
- Reward
 - Mobile application with an intangible reward (virtual coins for in app purchase, emoji)
 - Mobile application with a tangible reward (money or discount coupons (40))
 - Mobile application without a reward.

Further app categories can be described based on the connection of the application and how users can download it.

- Cloud and social connectivity
- Mobile application connected with the cloud to store and process data;
- Standalone application without a connection.

Table 1 (Additional file 1) shows this app classification with some examples and scientific papers related to them.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Search methods for identification of studies

Electronic searches

We will search the following databases:

- Cochrane Library
- MEDLINE
- Excerpta Medica database (Embase)
- PsycINFO
- IEEE Explore
- Web of Science (SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC)
- CINAHL
- LILACS.

Searching other resources

- ClinicalTrials.gov (<http://www.clinicaltrials.gov/>)
- Google Scholar (<https://scholar.google.com/>)
- European Medicine Agency (<http://www.ema.europa.eu/ema/>)
- United States Food and Drug Administration ([ww.fda.gov](http://www.fda.gov))
- Medicines and Healthcare Products Regulatory Agency (<https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency>)
- The World Health Organization (www.who.int/)
- Global Obesity Forum (previously International Association for the study of Obesity) (www.iaso.org)
- European Association for the study of Obesity (EASO) (easo.org)
- ICTRP Search Portal

Keywords used in the search strategy

- Obesity
- Overweight
- Smartphone apps
- Health apps
- m-health app
- Body mass index
- Weight gain
- Weight loss
- Hyperphagia

Preliminary search strategy for MEDLINE is enclosed as Additional file 2.

Data collection and analysis

Selection of studies

The review will follow the recommendations in the Cochrane Handbook for Systematic Reviews of Interventions and according to Keus et al and Jakobsen et al (41,42). The analyses will be performed using Review Manager (43) and Trial Sequential Analysis programme (44).

Two authors (RR and PP) will independently screen titles and abstracts. They will retrieve all relevant full text study/publication after which two authors will independently screen the full text in order to identify and record reasons for exclusion of the ineligible studies. We will resolve any disagreement through discussion. Trial selection will be displayed in an adapted flow diagram as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Additional file 3 reports the PRISMA checklist.

Data extraction and management

Data extraction will be performed independently by at least two authors, who will both compare

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

the extracted data. Disagreements will be resolved by a third author. We will assess duplicate publications and companion papers of a trial together to evaluate all available data simultaneously (maximise data extraction, correct bias assessment). Trial authors will be contacted by email to request any additional data which may not have been reported sufficiently or at all in the publication. Review Manager software will be used to extract data.

Assessment of risk of bias in included studies

The risk of bias of every included trial will be evaluated independently by at least two authors. In case of any disagreement, discrepancies will be discussed with a third author and resolved by consensus. The risk of bias will be assessed using the Cochrane’s ‘Risk of bias’ assessment tool (45,46) and the Cochrane Effective Practice and Organisation of Care Group’s guidance (46). We will evaluate the methodology in respect of:

- Random sequence generation
- Allocation concealment
- Blinding of participants and treatment providers
- Blinding of outcome assessment
- Incomplete outcome data
- Selective outcome reporting
- For profit bias
- Overall risk of bias

Classification of the trials will follow criteria defined in Additional File 4.

Meta-analysis

Both end-scores and change-from-baseline scores will be used to analyse continuous outcomes. If both end-scores and change-from-baseline scores are reported then only end-scores will be used. If only change-from-baseline scores are reported, these results together with end-scores will be

1.

321 analysed in the same meta-analyses (45). Exploratory outcomes will be analysed using change from
322 baseline scores.

323 Data will be meta-analysed by RevMan 5 statistical software. We will use STATA statistical software
(STATA 2015) in case of zero event trials, where RevMan 5 zero event handling is insufficient
(47,48). We will report effect estimate using mean difference with 95% confidence intervals.

326 Intervention effects will be assessed by both random-effects model meta-analyses and fixed-effect
model meta-analyses (27,44,49), using the more conservative point estimate of the two. Three
primary outcomes will be examined with $P \leq 0.025$ being statistically significant. An eight-step
procedure will be used to assess if the thresholds for significance are crossed. Five secondary
outcomes will be examined with $P \leq 0.017$ being statistically significant (38). The results of the
exploratory outcomes will be considered hypothesis generating only.

332 Analysis of all included studies will be compared to a sensitivity analysis of studies at low risk of bias.
333 If the results are similar, primary conclusions will be based at the time point closest to 12 months
334 on the overall analysis. If the results differ, primary conclusions will be based on studies with a low
335 risk of bias.

336 A table describing the types of serious adverse events in each trial will be provided.

337 338 **Trial Sequential Analysis**

339 Traditional meta-analysis runs the risk of random errors due to sparse data and repetitive testing of
340 accumulating data when updating reviews. Trial Sequential Analysis will thus be used to analyse the
341 outcomes in order to calculate the required information size and control the risks of type I errors
342 and type II errors (26,27,48).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For continuous outcomes, Trial Sequential Analysis will use the observed SD, a mean difference of the observed SD/2, an alpha of 2.5% for the three primary outcomes, an alpha of 1.67% for the five secondary outcomes and a beta of 10%, with adjustment for observed diversity (50,51). Mean differences (MDs) and the standardised mean difference will be expressed with 95% confidence intervals (CI) for continuous outcomes, as well as the Trial Sequential Analysis adjusted CIs for MDs. We intend to use the proportion in the control group and the diversity estimated in the meta-analysis to provide reliable results.

For dichotomous outcomes, Trial Sequential Analysis will use the proportion of participants with an outcome in the control group, a relative risk reduction of 20%, an alpha of 2.5% for primary outcomes, an alpha of 1.67% for secondary outcomes, and a beta of 10%, with adjustment for observed diversity. We will calculate risk ratios with 95% CI for dichotomous outcomes, as well as Trial Sequential Analysis adjusted CIs.

Subgroup analyses

Subgroup analysis when analysing the primary outcomes will be performed as follows:

- Trials at high risk of bias trials compared to trials at low risk of bias trials.
- Trials stratified according to experimental interventions.
- Trials stratified according to weight status: overweight, obese or morbidly obese at the entry into the trial (6).
- Trial stratified according to the control interventions.
- Complexity: trials with participants with no co-morbidities compared to trials with participants pre-existing co-morbidities.
- Trials in which the experimental intervention was evaluated by either the parents or the child after the treatment sessions had been delivered compared to trials in which the experimental intervention was not evaluated by either the parents or the child after the treatment sessions had been delivered.

We will use the formal test for subgroup interactions in Review Manager (43).

372

373 Sensitivity analysis

374 To assess the potential impact of the missing data for dichotomous outcomes, we will perform the
375 following sensitivity analyses:

- 376 • 'Best-worst-case' scenario: we will assume that all participants lost to follow-up in the
377 experimental group had no serious adverse events, including not developing any psychiatric
378 disease such as an eating disorder.
- 379 • Worst-best case scenario: all dropouts/participants lost from the experimental group, but
380 none from the control group experienced the outcome, including all randomised participants
381 in the denominator.

382 Statistical heterogeneity will be assessed by visual inspection of the forest plots and I^2 statistic
383 values (41). Underlying reasons behind statistical heterogeneity in meta-analyses will be
384 investigated by assessing trial characteristics.

386 Summary of findings table

387 A summary of findings table using each of the pre-specified primary and secondary outcomes will
388 be reported using the GRADE considerations for studies which contribute data to the meta-analyses
389 for the pre-specified outcomes (34,41, 52–65). Methods and recommendations described in Chapter
390 8 (Section 8.5) and Chapter 12 of the *Cochrane Handbook for Systematic Reviews of Interventions*
391 (66) will be followed using GRADEpro software.

393 DISCUSSION

394 The objective of the review will be to compare the benefits and harms of different categories of
395 mHealth apps for intervention of overweight in children. Currently, there are no systematic reviews
396 which specifically compare the effects of different typology of mHealth apps to interventions in
397 children with overweight. Previous systematic reviews in children have considered the efficacy of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

mobile health technologies more broadly in the role of weight management (65), but none have provided comprehensive coverage of the benefits and harms of mHealth apps nor an in-depth study of the different types of apps. Hence, this evidence will hopefully help children and adolescents, their parents, and health professionals to make informed treatment decisions. This review will also highlight any gaps in the evidence base of such interventions and in app structure which will help to shape the development and optimization of future potential interventions and apps.

ETHICS AND DISSEMINATION

Acknowledgements We would like to thank Sarah Louise Klingenberg, Information Specialist at the Copenhagen Trial Unit, Centre for Clinical Intervention Research for her guidance and assistance on developing search methods keywords for search strategies.

Author contributions IL, RR, PP, GA, CG and JCJ wrote the first draft of the protocol. PP, RR, IL, GA, JCJ and CG have revised the protocol. All authors read and approved the manuscript. IL is the guarantor for the review.

Funding This research received no specific grant from any funding agency.

Availability of data and materials Not applicable.

Competing interests None known.

Patient consent Not required.

Patient and Public Involvement No patient involvement.

Provenance and peer review Not commissioned, externally peer reviewed.

REFERENCES

1. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. *Int J Pediatr Obes*. 2007/09/29. 2006;1(1):11–25.
2. Lobstein T. The prevention of obesity in children. *Pediatr Endocrinol Rev*. 2006/01/31. 2004;1 Suppl 3:471–5.
3. de Onis M, Blossner M, Borghi E. Global prevalence and trends of overweight and obesity among preschool children. *Am J Clin Nutr*. 2010/09/24. 2010;92(5):1257–64.
4. Organisation WH. COSI: Childhood Obesity Surveillance Initiative. Copenhagen: WHO; 2018.
5. Organisation WH. Obesity and Overweight [Internet]. Copenhagen; 2016. Available from: <http://www.who.int/mediacentre/factsheets/fs311/en/>
6. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. *BMJ*. 2000/05/08. 2000;320(7244):1240–3.
7. Short CE, DeSmet A, Woods C, Williams SL, Maher C, Middelweerd A, et al. Measuring Engagement in eHealth and mHealth Behavior Change Interventions: Viewpoint of Methodologies. *J Med Internet Res*. 2018 Nov;20(11):e292.
8. Colquitt JL, Loveman E, O'Malley C, Azevedo LB, Mead E, Al-Khudairy L, et al. Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in preschool children up to the age of 6 years. *Cochrane Database Syst Rev*. 2016/03/11. 2016;3:Cd012105.
9. Al-Khudairy L, Loveman E, Colquitt JL, Mead E, Johnson RE, Fraser H, et al. Diet, physical activity and behavioural interventions for the treatment of overweight or obese adolescents aged 12 to 17 years. *Cochrane Database Syst Rev*. 2017;6:CD012691.
10. Mead E, Brown T, Rees K, Azevedo LB, Whittaker V, Jones D, et al. Diet, physical activity and behavioural interventions for the treatment of overweight or obese children from the age of 6 to 11 years. *Cochrane Database Syst Rev*. 2017/06/24. 2017;6:Cd012651.
11. Tate EB, Spruijt-Metz D, O'Reilly G, Jordan-Marsh M, Gotsis M, Pentz MA, et al. mHealth approaches to child obesity prevention: successes, unique challenges, and next directions. *Transl Behav Med*. 2013/12/03. 2013;3(4):406–15.
12. Anderson J, Kamphorst B. Ethics of e-coaching: Implications of employing pervasive computing to promote healthy and sustainable lifestyles. 2014. 351–356 p.
13. Baroni I, Nalin M, Coti Zelati M, Oleari E, Sanna A. Designing motivational robot: How robots might motivate children to eat fruits and vegetables. Vol. 2014. 2014.
14. Andreoni G, Perego P, Frumento E, editors. *m_Health Current and Future Applications*

1

2

3 464

4 465

5 466

6

7 467

8 468

9 469

10

11 470

12 471

13 472

14 473

15 474

16 475

17 476

18 477

19 478

20 479

21 480

22 481

23 482

24 483

25 484

26 485

27 486

28 487

29 488

30 489

31 490

32 491

33 492

34 493

35 494

36 495

37 496

38 497

39 498

40 499

41 500

42 501

43 502

44 503

45 504

46 505

47 506

48 507

49 508

50 509

51 510

52 511

53 512

54 513

55 514

56 515

57 516

58 517

59 518

60 519

[Internet]. Cham: Springer International Publishing; 2019. (EAI/Springer Innovations in Communication and Computing). Available from: <http://link.springer.com/10.1007/978-3-030-02182-5>

15. Bardus M, Smith JR, Samaha L, Abraham C. Mobile Phone and Web 2.0 Technologies for Weight Management: A Systematic Scoping Review. *J Med Internet Res*. 2015 Nov;17(11):e259.

16. Flores Mateo G, Granado-Font E, Ferré-Grau C, Montaña-Carreras X. Mobile Phone Apps to Promote Weight Loss and Increase Physical Activity: A Systematic Review and Meta-Analysis. *J Med Internet Res* [Internet]. 2015 Nov 10;17(11):e253. Available from: <http://www.jmir.org/2015/11/e253/>

17. Badawy SM, Kuhns LM. Texting and Mobile Phone App Interventions for Improving Adherence to Preventive Behavior in Adolescents: A Systematic Review. *JMIR mHealth uHealth* [Internet]. 2017 Apr 19;5(4):e50. Available from: <http://mhealth.jmir.org/2017/4/e50/>

18. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. *Ann Intern Med*. 2001/12/04. 2001;135(11):982–9.

19. Schunemann HJ, Wiercioch W, Brozek J, Etzeandía-Ikobaltzeta I, Mustafa RA, Manja V, et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. *J Clin Epidemiol*. 2016/10/08. 2017;81:101–10.

20. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised, controlled trials. *Ann Intern Med* [Internet]. 2012;157. Available from: <https://doi.org/10.7326/0003-4819-157-6-201209180-00537>

21. Savovic J, Jones H, Altman D, Harris R, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. *Heal Technol Assess*. 2012/09/20. 2012;16(35):1–82.

22. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *Jama*. 1995/02/01. 1995;273(5):408–12.

23. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. *BMJ*. 2008/03/05. 2008;336(7644):601–5.

24. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. *Cochrane Database Syst Rev*. 2012/12/14. 2012;12:Mr000033.

25. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? *Lancet*. 1998/09/24. 1998;352(9128):609–13.

26. Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta-analysis. *BMC Med Res Methodol* [Internet]. 2017;17(1):39. Available from: <https://doi.org/10.1186/s12874-017-0315-7>

27. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by

- quantifying diversity in random-effects model meta-analyses. *BMC Med Res Methodol*. 2010/01/01. 2009;9:86.
28. Boulos MN, Brewer AC, Karimkhani C, Buller DB, Dellavalle RP. Mobile medical and health apps: state of the art, concerns, regulatory control and certification. *Online J Public Heal Inf*. 2014/04/01. 2014;5(3):229.
 29. Gabrielli S, Dianti M, Maimone R, Betta M, Filippi L, Ghezzi M, et al. Design of a Mobile App for Nutrition Education (TreC-LifeStyle) and Formative Evaluation With Families of Overweight Children. *JMIR Mhealth Uhealth*. 2017/04/15. 2017;5(4):e48.
 30. Kim K, Christine H, Young E, Sabee C. Youth-centered design and usage results of the iN Touch mobile self-management program for overweight/obesity. Vol. 19. 2015.
 31. Ronimus M, Kujala J, Tolvanen A, Lyytinen H. Children's engagement during digital game-based learning of reading: The effects of time, rewards, and challenge. *Comput Educ*. 2014 Feb;71:237–46.
 32. Watters C, Author M, Abouzied A, Cox A, Kellar M, Kharrazi H, et al. Extending the Use of Games in Health Care. Vol. 5. 2006.
 33. Breton ER, Fuemmeler BF, Abrams LC. Weight loss-there is an app for that! But does it adhere to evidence-informed practices? *Transl Behav Med*. 2011/12/01. 2011;1(4):523–9.
 34. Garattini S, Jakobsen JC, Wetterslev J, Bertele V, Banzi R, Rath A, et al. Evidence-based clinical practice: Overview of threats to the validity of evidence and how to minimise them. *Eur J Intern Med*. 2016/05/11. 2016;32:13–21.
 35. Rashid R, Perego P, Condon L, Jakobsen JC, Lindschou J, Gluud C, et al. Health apps targeting children with overweight—a protocol for a systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials. *Syst Rev [Internet]*. 2020 Dec 11;9(1):28. Available from: <https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-020-1269-0>
 36. Ahuja B, Klassen AF, Satz R, Malhotra N, Tsangaris E, Ventresca M, et al. A review of patient-reported outcomes for children and adolescents with obesity. *Qual Life Res*. 2013/06/27. 2014;23(3):759–70.
 37. A. B. Social foundations of thought and action: A social cognitive theory. Englewood Cliffs: Prentice-Hall; 1986.
 38. Murtagh J, Dixey R, Rudolf M. A qualitative investigation into the levers and barriers to weight loss in children: opinions of obese children. *Arch Dis Child*. 2006/07/06. 2006;91(11):920–3.
 39. Puigdomenech E, Martin A, Lang A, Adorni F, Gomez SF, McKinstry B, et al. Promoting healthy teenage behaviour across three European countries through the use of a novel smartphone technology platform, PEGASO fit for future: study protocol of a quasi-experimental, controlled, multi-Centre trial. *BMC Med Inform Decis Mak [Internet]*. 2019 Dec 17;19(1):278. Available from: <https://bmcmmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-019-0958-x>
 40. Pedersen, Carmen and AH. Smart Technology for Health and Well-being. *J Fam Consum Sci*. 2018;110(2):55–6.
 41. Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. *BMC Med Res Methodol*.

- 1
- 2
- 3 551 2014/11/25. 2014;14:120.
- 4
- 5 552 42. Keus F, Wetterslev J, Gluud C, Laarhoven CJ. Evidence at a glance: error matrix approach
- 6 553 for overviewing available evidence. BMC Med Res Methodol [Internet]. 2010;10. Available
- 7 554 from: <https://doi.org/10.1186/1471-2288-10-90>
- 8
- 9 555 43. Collaboration C. Review Manager. Copenhagen: Nordic Cochrane Centre; 2014.
- 10
- 11 556 44. Thorlund K, Wetterslev J, Brok J, Imberger G et al EJ. User manual for trial sequential
- 12 557 analysis (TSA). [Internet]. 2011. Available from: www.ctu.dk/tsa
- 13
- 14 558 45. Davey J, Turner RM, Clarke MJ, Higgins JP. Characteristics of meta-analyses and their
- 15 559 component studies in the Cochrane Database of Systematic Reviews: a cross-sectional,
- 16 560 descriptive analysis. BMC Med Res Methodol. 2011/11/26. 2011;11:160.
- 17
- 18 561 46. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ.
- 19 562 2011/02/12. 2011;342:d549.
- 20
- 21 563 47. Demets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat
- 22 564 Med. 1987/04/01. 1987;6(3):341–50.
- 23
- 24 565 48. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm
- 25 566 evidence is reached in cumulative meta-analysis. J Clin Epidemiol [Internet]. 2008;61.
- 26 567 Available from: <https://doi.org/10.1016/j.jclinepi.2007.03.013>
- 27
- 28 568 49. Keus F, Wetterslev J, Gluud C, Gooszen HG, van Laarhoven CJ. Trial sequential analyses of
- 29 569 meta-analyses of complications in laparoscopic vs. small-incision cholecystectomy: more
- 30 570 randomized patients are needed. J Clin Epidemiol. 2009/12/17. 2010;63(3):246–56.
- 31
- 32 571 50. Proposal for a good clinical practice directive. Bull Med Ethics. 2001/10/20. 1998;No. 135:6–
- 33 572 11.
- 34
- 35 573 51. StataCorp. StataCorp Statistical Software [Internet]. Release 14. College Station: StataCorp
- 36 574 LP; 2014. Available from: <http://www.stata.com>
- 37
- 38 575 52. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an
- 39 576 emerging consensus on rating quality of evidence and strength of recommendations. BMJ.
- 40 577 2008/04/26. 2008;336(7650):924–6.
- 41
- 42 578 53. Schunemann HJ, Best D, Vist G, Oxman AD. Letters, numbers, symbols and words: how to
- 43 579 communicate grades of evidence and recommendations. Cmaj. 2003/10/01.
- 44 580 2003;169(7):677–80.
- 45
- 46 581 54. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new
- 47 582 series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2010/12/28.
- 48 583 2011;64(4):380–2.
- 49
- 50 584 55. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of
- 51 585 evidence and strength of recommendations. BMJ. 2004/06/19. 2004;328(7454):1490.
- 52
- 53 586 56. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1.
- 54 587 Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol.
- 55 588 2011/01/05. 2011;64(4):383–94.
- 56
- 57 589 57. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2.
- 58 590 Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011/01/05.
- 59 591 2011;64(4):395–400.

58. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). *J Clin Epidemiol.* 2011/01/21. 2011;64(4):407–15.
59. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. *J Clin Epidemiol.* 2011/08/02. 2011;64(12):1277–82.
60. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. *J Clin Epidemiol.* 2011/08/02. 2011;64(12):1294–302.
61. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence--indirectness. *J Clin Epidemiol.* 2011/08/02. 2011;64(12):1303–10.
62. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. *J Clin Epidemiol.* 2011/08/02. 2011;64(12):1311–6.
63. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. *J Clin Epidemiol.* 2012/05/01. 2013;66(2):151–7.
64. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables--binary outcomes. *J Clin Epidemiol.* 2012/05/23. 2013;66(2):158–72.
65. Darling KE, Sato AF. Systematic Review and Meta-Analysis Examining the Effectiveness of Mobile Health Technologies in Using Self-Monitoring for Pediatric Weight Management. *Child Obes.* 2017/05/05. 2017;13(5):347–55.
66. Chandler J, Cumpston M, Li T, Page MJ, Welch VA. *Cochrane handbook for systematic reviews of interventions.* John Wiley & Sons; 2019.

Appendices

Additional File 1: Table 1 Classification of mHealth apps.


Additional File 2: Preliminary search strategy for MEDLINE (Ovid).

Additional File 3: Prisma-P+ checklist.

Additional File 4: Classification of randomised trials at low and high risk of bias.

Images legends

Figure 1: Overweight and obesity prevalence values based on WHO definition - COSI 2015-2017 (4)



Overweight and obesity prevalence values based on WHO definition - COSI 2015-2017 (4)

Reporting checklist for protocol of a systematic review.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

			Page Number
Reporting Item			
Title			
Identification	#1a	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	n/a
Registration			
	#2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors			
Contact	#3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1

1	Contribution	#3b	Describe contributions of protocol authors and identify the guarantor of the review	16
2				
3				
4				
5	Amendments			
6				
7		#4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	n/a
8				
9				
10				
11				
12				
13				
14	Support			
15				
16				
17	Sources	#5a	Indicate sources of financial or other support for the review	16
18				
19	Sponsor	#5b	Provide name for the review funder and / or sponsor	n/a
20				
21	Role of sponsor or funder	#5c	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	n/a
22				
23				
24				
25	Introduction			
26				
27				
28	Rationale	#6	Describe the rationale for the review in the context of what is already known	2
29				
30				
31				
32	Objectives	#7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	6
33				
34				
35				
36				
37	Methods			
38				
39				
40	Eligibility criteria	#8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6
41				
42				
43				
44				
45				
46				
47	Information sources	#9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	9
48				
49				
50				
51				
52	Search strategy	#10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	10
53				
54				
55				
56				
57				
58	Study records -	#11a	Describe the mechanism(s) that will be used to manage	11
59				
60				

data management		records and data throughout the review	
Study records - selection process	#11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	11
Study records - data collection process	#11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	11
Data items	#12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	7
Outcomes and prioritization	#13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	7
Risk of bias in individual studies	#14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	11
Data synthesis	#15a	Describe criteria under which study data will be quantitatively synthesised	14
Data synthesis	#15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I ² , Kendall's τ)	14
Data synthesis	#15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	11
Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the type of summary planned	n/a
Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	12

1

Confidence in

#17

Describe how the strength of the body of evidence will be

14

2

3

cumulative

assessed (such as GRADE)

4

evidence

5

6

7

The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License

8

CC-BY 4.0. This checklist was completed on 24. June 2019 using <https://www.goodreports.org/>, a

9

10

tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

**Search strategies for
Apps vs no apps
Preliminary searches performed 23 April 2019**

Total number of records identified: 4494 records
Number of duplicates excluded: 743 records
Number of records in final list: 3751 records

Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (2019, Issue 4) (546 hits)

- #1 MeSH descriptor: [Obesity] explode all trees
- #2 MeSH descriptor: [Hyperphagia] explode all trees
- #3 MeSH descriptor: [Body Mass Index] explode all trees
- #4 MeSH descriptor: [Weight Gain] explode all trees
- #5 MeSH descriptor: [Weight Loss] explode all trees
- #6 MeSH descriptor: [Anti-Obesity Agents] 1 tree(s) exploded
- #7 (Pickwick* syndrom* or Prader willi syndrom* or obes* or adipos* or overweight* or 'over weight*' or overeat* or 'over eat*' or 'over feed*' or overfeed* or binge eating disorder* or 'fat overload' syndrom* or (weight and (gain or cycling or reduc* or loss or losing or maint* or decreas* or watch* or diet* or control*))) .ti,ab
- #8 #1 or #2 or #3 or #4 or #5 or #6 or #7
- #9 MeSH descriptor: [Mobile Applications] explode all trees
- #10 ((mobile or smartphone or telephone or virtual or digital or wellness or medical or dietary or physical activity or intervention or treatment or weight or calorie) and (app or coach or tracker))
- #11 (m*health or mobile health or p*health or personal health or 'in touch' or txt2bfit or pegaso or fitbit or collective intelligence or 'move it' or myfitnesspal)
- #12 #9 or #10 or #11
- #13 #8 and #12

MEDLINE Ovid (1946 to April 2019) (510 hits)

- 1. exp Obesity/
- 2. exp Hyperphagia/
- 3. exp body mass index/
- 4. exp Weight Gain/
- 5. exp Weight Loss/
- 6. exp Anti-Obesity Agents/
- 7. (Pickwick* syndrom* or Prader willi syndrom* or obes* or adipos* or overweight* or 'over weight*' or overeat* or 'over eat*' or 'over feed*' or overfeed* or binge eating disorder* or 'fat overload' syndrom* or (weight and (gain or cycling or reduc* or loss or losing or maint* or decreas* or watch* or diet* or control*))) .ti,ab.
- 8. 1 or 2 or 3 or 4 or 5 or 6 or 7
- 9. exp Mobile Applications/
- 10. ((mobile or smartphone or telephone or virtual or digital or wellness or medical or dietary or physical activity or intervention or treatment or weight or calorie) and (app or coach or tracker)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
- 11. (m*health or mobile health or p*health or personal health or 'in touch' or txt2bfit or pegaso or fitbit or collective intelligence or 'move it' or myfitnesspal).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
- 12. 9 or 10 or 11
- 13. 8 and 12
- 14. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
- 15. 13 and 14

Embase Ovid (1974 to April 2019) (802 hits)

- 1. exp obesity/
- 2. exp hyperphagia/

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 3. exp body mass/
- 4. exp body weight gain/
- 5. exp body weight loss/
- 6. exp antiobesity agent/
- 7. (Pickwick* syndrom* or Prader willi syndrom* or obes* or adipos* or overweight* or 'over weight*' or overeat* or 'over eat*' or 'over feed*' or overfeed* or binge eating disorder* or 'fat overload' syndrom* or (weight and (gain or cycling or reduc* or loss or losing or maint* or decreas* or watch* or diet* or control*))) .ti,ab.
- 8. 1 or 2 or 3 or 4 or 5 or 6 or 7
- 9. exp mobile application/
- 10. ((mobile or smartphone or telephone or virtual or digital or wellness or medical or dietary or physical activity or intervention or treatment or weight or calorie) and (app or coach or tracker)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
- 11. (m*health or mobile health or p*health or personal health or 'in touch' or txt2bfit or pegaso or fitbit or collective intelligence or 'move it' or myfitnesspal).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
- 12. 9 or 10 or 11
- 13. 8 and 12
- 14. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
- 15. 13 and 14

LILACS (Bireme; 1982 to April 2019) (24 hits)

(Pickwick\$ syndrom\$ or Prader willi syndrom\$ or obes\$ or adipos\$ or overweight\$ or 'over weight\$' or overeat\$ or 'over eat\$' or 'over feed\$' or overfeed\$ or binge eating disorder\$ or 'fat overload' syndrom\$ or (weight and (gain or cycling or reduc\$ or loss or losing or maint\$ or decreas\$ or watch\$ or diet\$ or control\$))) [Words] and (((mobile or smartphone or telephone or virtual or digital or wellness or medical or dietary or physical activity or intervention or treatment or weight or calorie) and (app or coach or tracker)) or (m\$health or mobile health or p\$health or personal health or 'in touch' or txt2bfit or pegaso or fitbit or collective intelligence or 'move it' or myfitnesspal)) [Words]

Science Citation Index Expanded (SCI-EXPANDED) (1900 to April 2019), Social Sciences Citation Index (SSCI) (1956 to April 2019), Arts & Humanities Citation Index (A&HCI) (1975 to April 2019), Conference Proceedings Citation Index- Science (CPCI-S) (1990- April 2019), Conference Proceedings Citation Index- Social Science & Humanities (CPCI-SSH) (1990- April 2019), Emerging Sources Citation Index (ESCI) (2015 to April 2019), Web of Science Core Collection: Chemical Indexes Current Chemical Reactions (CCR-EXPANDED) (1986 to April 2019), Index Chemicus (IC) (1993 to April 2019) (Web of Science) (2612 hits)

- #7 #6 AND #5
- #6 TS=(random* or blind* or placebo* or meta-analys*)
- #5 #4 AND #1
- #4 #3 OR #2
- #3 TS=(m*health or mobile health or p*health or personal health or 'in touch' or txt2bfit or pegaso or fitbit or collective intelligence or 'move it' or myfitnesspal)
- #2 TS=((mobile or smartphone or telephone or virtual or digital or wellness or medical or dietary or physical activity or intervention or treatment or weight or calorie) and (app or coach or tracker))
- #1 TS=(Pickwick* syndrom* or Prader willi syndrom* or obes* or adipos* or overweight* or 'over weight*' or overeat* or 'over eat*' or 'over feed*' or overfeed* or binge eating disorder* or 'fat overload' syndrom* or (weight and (gain or cycling or reduc* or loss or losing or maint* or decreas* or watch* or diet* or control*)))

Table 1 Classification of mhealth apps

Category	Name of the app	Authors	Year	Paper Title
App with device	Collective Intelligence	Addo et al	2013	Toward collective intelligence for fighting obesity
Standalone	iN Touch	Kim et al	2015	Youth-centered Design and Usage Results of the iN Touch Mobile Self-management Program for Overweight/Obesity
Real (Human)	Personal Wellness Coach	Asselin et al	2005	Implementation and evaluation of the personal wellness coach
Virtual	Move it move it	Frost et al	2012	We Like to Move It Move It!: Motivation and Parasocial Interaction
None	iN Touch	Kim et al	2015	Youth-centered Design and Usage Results of the iN Touch Mobile Self-management Program for Overweight/Obesity
Reminder	Txt2Bfit	Partridge et al	2015	Effectiveness of a mHealth Lifestyle Program With Telephone Support (TXT2BFIT) to Prevent Unhealthy Weight Gain in Young Adults: Randomized Controlled
Smart Suggestion	Teenagers and Digital Coaching	Kettunen et al	2018	Can Sport and Wellness Technology be My Personal Trainer?—Teenagers and Digital Coaching
None	MyFitnessPal	Levinson et al	2017	My Fitness Pal calorie tracker usage in the eating disorders
Intangible				**PEGASO DSAHBOARD (not published)
Tangible	Pegaso City	Caon et al	2016	PEGASO Companion: A Mobile App to Promote Healthy Lifestyles Among Adolescents
None	Fitbit for Obese	Yoost et al	2018	The Use of Fitbit Technology Among Rural Obese Adolescents
Connected	Collective Intelligence	Addo et al	2013	Toward collective intelligence for fighting obesity
Standalone	Personal Wellness Coach	Asselin et al	2005	Implementation and evaluation of the personal wellness coach

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Assessment of risk of bias in included studies

Random sequence generation

Low risk: If sequence generation was achieved using computer random number generator or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were also considered adequate if performed by an independent adjudicator.

Unclear risk: If the method of randomisation was not specified, but the trial was still presented as being randomised.

High risk: If the allocation sequence is not randomised or only quasi-randomised. These trials will be excluded.

Allocation concealment

Low risk: If the allocation of patients was performed by a central independent unit, on-site locked computer or identical-looking numbered sealed envelopes.

Uncertain risk: If the trial was classified as randomised but the allocation concealment process was not described.

High risk: If the allocation sequence was familiar to the investigators who assigned participants.

Blinding of participants and treatment providers

Low risk: If the participants and the treatment providers were blinded to intervention allocation and this was described.

Uncertain risk: If the procedure of blinding was insufficiently described.

High risk: If blinding of participants and the treatment providers was not performed.

Blinding of outcome assessment

Low risk of bias: If it was mentioned that outcome assessors were blinded and this was described.

Uncertain risk of bias: If it was not mentioned if the outcome assessors in the trial were blinded or the extent of blinding was insufficiently described.

High risk of bias: If no blinding or incomplete blinding of outcome assessors was performed.

Incomplete outcome data

Low risk of bias: If missing data were unlikely to make treatment effects depart from plausible values. This could be either (1) there were no drop-outs or withdrawals for all outcomes, or (2) the numbers and reasons for the withdrawals and drop-outs for all outcomes were clearly stated and could be described as being similar to both groups. Generally, the trial is judged as at a low risk of bias due to incomplete outcome data if drop-outs are less than 5%. However, the 5% cut-off is not definitive.

Uncertain risk of bias: If there was insufficient information to assess whether missing data were likely to induce bias on the results.

High risk of bias: If the results were likely to be biased due to missing data either because the pattern of drop-outs could be described as being different in the two intervention groups or the trial used improper methods in dealing with the missing data (e.g. last observation carried forward).

Selective outcome reporting

Low risk of bias: If a protocol was published before or at the time the trial was begun and the outcomes specified in the protocol were reported on. If there is no protocol

or the protocol was published after the trial has begun, reporting of serious adverse events will grant the trial a grade of low risk of bias.

Uncertain risk of bias: If no protocol was published and the outcome of serious adverse events were not reported on.

High risk of bias: If the outcomes in the protocol were not reported on.

Other risks of bias

Low risk of bias: If the trial appears to be free of other components (for example, academic bias or for-profit bias) that could put it at risk of bias.

Unclear risk of bias: If the trial may or may not be free of other components that could put it at risk of bias.

High risk of bias: If there are other factors in the trial that could put it at risk of bias (for example, authors conducted trials on the same topic, for-profit bias, etc.).

Overall risk of bias

Low risk of bias: The trial will be classified as overall 'low risk of bias' only if all of the bias domains described in the above paragraphs are classified as 'low risk of bias'.

High risk of bias: The trial will be classified as 'high risk of bias' if any of the bias risk domains described in the above are classified as 'unclear' or 'high risk of bias'.

We will assess the domains 'blinding of outcome assessment', 'incomplete outcome data', and 'selective outcome reporting' for each outcome result. Thus, we can assess the bias risk for each outcome assessed in addition to each trial. Our primary conclusions will be based on the results of our primary outcome results with overall low risk of bias. Both our primary and secondary conclusions will be presented in the summary of findings tables.